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EXECUTIVE SUMMARY 
 
This study focused primarily on patterns of drug use, injecting practices, risk 
behaviours for infectious disease, and experiences with treatment and health 
services among injecting drug users (IDUs) in Northern Ireland.  The data for the 
study were collected through semi-structured interviews conducted between 
December 2003 and September 2004.  Sample criteria included 1) 18 years or 
older and 2) injection of one or more drugs (excluding insulin or other medication 
that was prescribed for injection) within the 30 days prior to the interview.  
Various strategies were used to recruit respondents for an interview and the 
findings are based on interview data collected from 90 respondents who met the 
study criteria.     
 
Females comprised 30% of the sample and respondents’ ages ranged from 19 to 
53 years (mean=31; median=30; mode=25.5).  At the time of the interview, 45% 
resided in the Eastern Board, 41% resided in the Northern Board, 6% resided in 
the Southern Board, and 8% lived in the Western Board.  We interviewed people 
who resided in one of five of the six counties in Northern Ireland although despite 
our efforts, we were unable to recruit from County Fermanagh.  In addition to 
Belfast, respondents resided in one of 17 different towns, cities, villages or rural 
areas within Northern Ireland.  Several methods were used to recruit 
respondents and this approach probably added to the diversity of the sample.            
 
The average age at first injection was 23 years (range=13 to 40 years) and 75% 
of respondents had injected heroin at initiation.  Two-thirds (66%) of the sample 
had initiated injection in Northern Ireland.  On average, respondents had injected 
for 8.6 years and 61% of the sample had injected during the 24-hour period 
before the interview.  The number of injections ranged from 1 to 180 during the 
30-day period prior to the interview.     
 
Nearly all respondents had used a new needle and syringe during most injection 
episodes in the 30-day period prior to the interview.  However, within that 30-day 
period, various circumstances and settings contributed to the borrowing of used 
needles/syringes among some respondents.  The majority of respondents had 
injected with at least one other person in the past 30 days.  Although several had 
injected with new needles and syringes during this time period, most had used 
filters, spoons/stericups, and water that had been used by another injector.  The 
social context of injection settings, the perceived trust of other injectors, as well 
as a lack of knowledge regarding infectious disease transmission, contributed to 
the borrowing of injecting equipment other than needles and syringes.     
 
The vast majority of respondents had used a needle and syringe exchange 
scheme in Northern Ireland at some point since 2001.  Favourable reports about 
the scheme were noted by several respondents.  However, the data also showed 
a consistent pattern with regards to negative feedback about one exchange in 
particular.  Additionally, the results showed that various factors associated with 
needle exchange scheme contributed to engaging in risk behaviours for 
infectious disease. These factors included restrictions on the number of needles 
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that were distributed at each visit, closure at weekends, evenings and holidays, 
the quality of injecting equipment, perceived stigma regarding “injector” status, 
and concerns about confidentiality in exchanges.        
 
The data indicated that police practices contributed to risk taking among some 
respondents who had become greatly concerned about carrying used injection 
equipment.  We observed this pattern primarily in the Northern Board.     
 
We did not conduct tests for antibodies to hepatitis C, hepatitis B core antigen, or 
HIV.  Nor did we ask respondents about test results.  Nevertheless, 30% of 
respondents who were certain that they had been tested for hepatitis C reported 
to us that they had been diagnosed with hepatitis C.  The data suggests that this 
figure is very likely to be an underestimate because some people had never been 
tested, most respondents had not been tested on a regular basis and many had 
not been tested for long periods of time.  Respondents residing in the Eastern 
Board reported knowing several injectors with hepatitis C and some reported that 
most or all of the IDUs who they knew had hepatitis C.  In comparison, the 
majority of respondents residing in the Northern Board knew very few injectors 
with hepatitis C.  No-one reported that they had antibodies to hepatitis B core 
antigen and only 17 respondents reported that they had been fully immunised 
against hepatitis B.  Approximately 15% of respondents had never been tested 
for HIV antibodies and 6% did not know whether they had been tested.   
 
A total of 39% of respondents had consumed no alcohol during the 30-day period 
prior to the interview.  Additionally, 37% had consumed small amounts of alcohol, 
i.e., a few drinks, during the same time period.  However, several reported that 
they drank quite frequently prior to using heroin.  Some respondents who were 
participating in a programme of Subutex maintenance reported that their alcohol 
consumption had increased since reducing their intake of opiates.   
 
A number of respondents were consuming benzodiazepines on a daily basis.  A 
total of 37% were in receipt of a prescription for diazepam whereas others 
purchased them from street or Internet sources, these drugs often differed in 
appearance from prescribed benzodiazepines.  Still others obtained them at no 
cost from partners, relatives, or friends.  Some IDUs had been prescribed the 
drugs for years, long before they ever injected.  Most respondents had no 
knowledge regarding the dangers of benzodiazepine withdrawal, although, some 
had experienced lengthy withdrawal periods characterised by severe effects.       
 
Sexual activity was rare among many long-term IDUs who had a partner who 
was also an IDU.  However, a number of young male injectors had female 
partners who had little experience with drugs except for weekend use of alcohol 
or cannabis.   
 
Some respondents reported being in good physical health, although others 
complained about venous damage which made injection into the sites either 
impossible or improbable.  Several males and females reported injecting into the 
groin.  With regards to emotional health, we observed that several respondents 
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reported a history of depression and a number had been prescribed anti-
depressants.   
 
The interview data revealed three broad groups of IDUs: 1) respondents who 
were in contact with drug services (statutory or voluntary) at the time of the 
interview (40%), 2) respondents with a history of engaging or attempting to 
engage in drug treatment but who were not in contact with services at the time of 
the interview (43%), and 3) respondents who had never been in contact with drug 
treatment services (17%).  We found considerable differences across board 
areas.  A total of 62% of respondents from the Northern Board were in contact 
with treatment services at the time of the interview, compared to 23% of 
respondents from the Eastern Board.  Four of seven respondents from the 
Western Board were in contact with drug services in Northern Ireland.  None of 
the five respondents from the Southern Board were in contact with drug services 
at the time of the interview although all expressed an interest in treatment.  The 
results suggested that drug services can provide various and effective assistance 
to IDUs, however, the data revealed a number of barriers to accessing treatment 
services.   
 
The findings indicated that female injectors were significantly less likely than 
males to be in contact with drug services at the time of the interview 
(females=30%; males=44%).  Females also were more likely than males to 
depend on someone else to inject them and females with IDU partners were 
more likely to inject with their partner only, compared to males with IDU partners.  
Females with children were concerned about the placement of children in the 
event that the female’s injecting status became known.  They were more likely 
than males to exercise caution when visiting pharmacy-based needle exchanges, 
were less likely to be tested for infectious diseases and were less likely to contact 
GPs about drug-related problems.       
 
Several injectors requested advocacy, support or information from one or both 
interviewers.  Generally, we contacted professionals who had expertise in these 
areas and then disseminated the information to the respondents through follow-
up contact.  Our expanded role was unexpected and reflected a major gap in 
services that could otherwise assist IDUs.   
 
The results of the study have several implications for policy and additional 
research.   Based on the findings generated from the interview data, the report 
concludes with 20 recommendations.    
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INTRODUCTION 
 
Studies of injecting drug use (IDU) are rare in Northern Ireland, therefore, little is 
known about the extent of risk behaviours, infectious disease, treatment 
experiences and lifestyles of respondents who inject drugs.  One (now dated) 
study of largely Belfast heroin users (the majority of whom were IDUs) found that 
respondents had engaged in various risk behaviours for infectious disease and 
had little knowledge about how infectious diseases could be transmitted.  
Moreover, very few heroin users in that sample had completed drug treatment, 
despite lengthy injection careers and substantial health problems (McElrath, 
2001).   
 
Recent information pertaining to IDU in Northern Ireland is available from various 
databases.  The Northern Ireland Drug Misuse Database (DMD) records 
information on respondents presenting at a statutory or voluntary drug agency.  
An individual must consent before the data can be forwarded to the DMD.  In 
2002-2003, the DMD data showed that 21% of respondents presenting at a drug 
service had injected previously (Department of Health, Social Services and 
Public Safety, 2003).  Data collected in 2003 for the Northern Ireland Drug 
Addicts Index identified 62 newly notified respondents whose injecting behaviour 
was known (Department of Health, Social Services and Public Safety, 2004).  A 
total of 79% of this group were injecting compared to 45% of respondents who 
had been re-notified.  Additionally, pharmacy-based needle exchanges 
distributed approximately 82,000 needles and syringes between 1 April 2003 and 
31 March 2004.  A total of 7,508 exchanges were made during the 12-month 
period, and females accounted for approximately 17% of visits to the exchanges 
(Drug and Alcohol Information and Research Unit, 2004).  In 2002, the Unlinked 
Anonymous Prevalence Monitoring Programme was extended to Northern 
Ireland.  The research was based on data collected from 77 respondents who 
were attending one of five drug services in the region (Health Protection Agency, 
2003).  A total of 88% had injected during the preceding 12-month period prior to 
data collection, and 60% (N=46) had injected in the previous four weeks.  Among 
those who had injected in the past four weeks, 42% had “shared” needles and 
syringes.  That figure was higher than that reported for all of England and Wales. 
Also, 62% reported “sharing” other injection equipment during that four-week 
period.  The authors found that 16% of the respondents had antibodies to 
hepatitis C virus and 3% had antibodies to hepatitis B core antigen.  None of the 
77 study participants tested positive for HIV antibodies.   
 
These indicators serve as useful baselines with regards to IDU, injecting 
behaviour and prevalence of hepatitis B and C and HIV among IDUs who were in 
contact with services in Northern Ireland.  In recent years, studies conducted in 
various countries have focused on out-of-treatment drug users, and some of 
these studies have compared this group with respondents who have undergone 
drug treatment.  From this literature we know that these two groups often differ in 
terms of their frequency of drug use or injection (Booth, Crowley and Zhang, 
1996; Meandzija et al., 1994), risk behaviours for HIV and other infectious 
disease (Corsi, Kwiakowski and Booth, 2002; Judd et al., 1999), and various 
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social and health problems (Kuebler, Hausser, and Gernasoni, 2000).  In 
particular, out-of-treatment injectors appear to be at greater risk for infectious 
disease compared to IDUs who have undergone drug treatment.  For example, 
Friedman et al. (1995) found that even in low HIV prevalence US cities, out-of-
treatment injectors were significantly more likely than injectors in treatment to 
seroconvert to HIV infection during the study period.  A study by Metzger et al. 
(1993) supported these findings in that drug treatment lowered the rate of HIV 
seroconversion among IDUs.  One London-based study found that the 
prevalence of HIV infection was higher among female IDUs recruited from non-
treatment settings compared to treatment settings (Judd et al., 1999).    
 
The purpose of the present study was to compare IDUs in contact with drug 
services with IDUs who were not.  The research focused primarily on patterns of 
drug use, injecting practices and risk behaviours for infectious disease, and 
overall health among IDUs in Northern Ireland.  We also examined individuals’ 
experiences with treatment and health services.  In this report, we describe the 
methodology, present the main findings, and offer a number of recommendations 
based on those findings.   
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METHODOLOGY 
 
The primary data for this study were collected through face-to-face, semi-
structured interviews with injecting drug users (IDU) in Northern Ireland.  Criteria 
used for interview eligibility were 1) 18 years or older and 2) injection of one or 
more drugs (excluding insulin or other medication that was prescribed for 
injection) within the 30 days prior to the interview.  A total of 93 respondents were 
interviewed and 90 respondents met these criteria.  The study criteria have 
important implications for the findings.  Other researchers have defined “current 
injectors” as respondents who have injected a drug in the past two months (e.g., 
WHO Collaborative Study Group, 1993) or respondents who have injected during 
the past six months (e.g., Peters et al., 1998).   Clearly, studies that use a longer 
time frame to capture “current injectors” have the potential for recruiting larger 
numbers of respondents.  Indeed, Peters et al. (1998) used the sample criterion 
of injection during the six months prior to the interview because the authors were 
concerned that a more limited time period would create problems in recruiting 
respondents.   
 
Several methods were used to recruit respondents for interviews.  First, 
announcements of the study were distributed within pharmacies that offered 
needle exchange.  Second, study announcements were placed on notice boards 
in venues where current injectors might frequent, e.g., health centres, in or near 
the offices of general practitioners.  Third, we contacted the South Belfast Drug 
Outreach Team and community workers in various sites and asked them to 
distribute information about the study.  Fourth, we distributed “business cards” to 
personal contacts and “street sources” who we believed might have access to 
respondents who injected.  The cards contained information about the study and 
telephone numbers for the interviewers.  Fifth, we relied upon snowball sampling 
or “chain referral” techniques (Biernacki & Waldorf 1981) whereby respondents 
who completed an interview were asked to refer friends and acquaintances.  For 
ethical reasons we tended to avoid asking for referrals from respondents who 
were attempting to “get clean” because some of these people wished to distance 
themselves from the wider injecting community.  We monitored referrals carefully 
and generally did not permit more than three or four referrals from any one 
respondent. Midway into the data collection stage we distributed copies of the 
study announcement to various drug services in Northern Ireland.  These 
multiple sources of recruitment had two advantages, 1) increased the probability 
of recruiting more people into the study, and 2) increased the potential for sample 
diversity.     
 
Interviews were conducted between December 2003 and September 2004.  Two 
respondents – both of whom were female – served as interviewers.  Before data 
collection, the second interviewer was trained in terms of the interview guide, 
ethical issues pertaining to confidentiality and anonymity and other issues 
relating to qualitative fieldwork.  The interview guide was developed, piloted on 
the first five respondents and minor revisions were made throughout the study 
when we learned that questions were inappropriate or worded improperly.  A 
copy of the interview guide is included in the Appendix. 
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Interviews in Belfast generally were conducted in university offices that offered a 
great deal of privacy, or in other venues convenient to the respondent (e.g., 
private residences). Interviews with respondents who lived outside of Belfast 
were conducted largely in private residences as well as community agencies, or 
semi-public areas.      
 
Prior to the collection of data, the study received approval by the Queen’s 
University Medical Ethics Committee.  The first author also met with this 
Committee to discuss issues regarding the study.  An Informed Consent 
Statement was developed and distributed to study participants before the 
interview commenced, and respondents were paid £20 for a completed interview.  
Interviews were conducted within a one- to two-hour time period and focused on 
issues related to first and most recent injection experiences, patterns of injection 
and drug use generally, perceptions about drug dependency, risk behaviours for 
infectious diseases, experiences with general practitioners, chemists and other 
health professionals, history of and experiences with drug treatment, experiences 
with drug outreach, issues pertaining to emotional and physical health, and 
related items.   Respondents were encouraged to go beyond the subject area of 
the research instrument, when appropriate.  About half of the Interviews were 
taped and subsequently transcribed by the first author.  Very detailed notes were 
taken during the remainder of the interviews.  Audio tapes were secured outside 
the jurisdiction until they were transcribed, and then they were destroyed.   
 
For ethical reasons, it should be noted that the first author is a member of the 
advisory group for the South Belfast Drug Outreach Team.  However, the second 
author conducted the vast majority of interviews in Belfast.  Further, although 6% 
of the respondents were referred to the study by the Outreach Team, we also 
interviewed people who had made contact with the Outreach Team but who had 
not been referred by the Team.  The first author is also a member of the advisory 
group for a voluntary drug service in Northern Ireland.  We believe that these 
external roles did not affect the nature of questioning or the interpretation of 
results.     





These results are based on interviews with 90 respondents who had injected one 
or more drugs within the 30-day period prior to the interview.  Females comprised 
30% of the overall sample (males=70%).  However, a significantly higher 
percentage of females were interviewed in the Eastern Board (40%) compared to 
the Northern Board (22%).1 Respondents’ ages ranged from 19 to 53 years 
(mean=31, median=30, mode=25.5). On average, females were slightly older 
than males (32 and 30 years respectively).  Approximately 35% of respondents 
lived with a partner at the time of the interview, 23% lived with a relative, 6% lived 
with house or flatmates, 5% lived with their children only, and 31% lived alone.  A 
total of 21% of respondents were employed at the time of the interview, although 
several had worked in full- or part-time employment previously.  Approximately 
one-third of the sample (32%) had achieved a level of education of O 
Levels/GCSEs or beyond.   
 
At the time of the interview, 45% resided in the Eastern Board, 41% resided in 
the Northern Board, 6% resided in the Southern Board, and 8% lived in the 
Western Board.  We interviewed people who resided in one of five of the six 
counties in Northern Ireland although despite our efforts, we were unable to 
recruit from County Fermanagh.  In addition to Belfast, respondents resided in 
one of 17 different towns, cities, villages or rural areas within Northern Ireland.  
Respondents had learned about the study through needle exchange schemes 
(27%), friends or acquaintances who might have been eligible for the study 
(25%), friends or acquaintances who participated in the study (19%), personal 
contacts of the research team (8%), the South Belfast Drug Outreach Team 
(6%), drug services (12%), and other statutory or voluntary agencies (3%).         
 
 
Initiation into Injecting Drug Use 
 
The average age at first injection was 23 years (range=13 to 40 years).  On 
average, males initiated injection at significantly younger ages than females 
(males=22 years; females=24 years).  The average age at first injection was the 
same in the Eastern and Northern Boards.  At initiation, most respondents had 
injected heroin (75%).  Others had initiated injection with other opiates (e.g., 
Morphine Sulphate Tablets, Palfium, Nubain), cocaine hydrochloride (powder) or 
crack cocaine, amphetamine, MDMA, LSD, barbiturates or steroids.  Two-thirds 
(66%) of the sample had initiated injection in Northern Ireland.  Additionally, 
among those respondents who had initiated in Northern Ireland, 90% had done 
so between 1995 and 2004.     
 
                                                 
1 In most instances, we were unable to compare results from the Western and Southern Boards 
because of the few respondents who participated from those areas.    
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Among respondents who had reported that heroin was the first drug that they 
injected, 88% had smoked heroin prior to that experience.  Some had smoked for 
considerable lengths of time prior to injecting (i.e., two years or more), and 
despite being in the presence of injectors on several occasions, they avoided 
injecting for long periods of time.  For example, a 32-year old female injected for 
the first time a week before the interview.  She had smoked heroin at the age of 
29 and continued smoking for three years. A former male partner had been an 
IDU although she never injected with him.   
 
For the majority of respondents, the injection was not planned.  Many had little 
knowledge about the injection process and some knew very little about the drug 
that was injected:   
 
“In July 1998 – I’ll never forget the month and that day.  I was at a party 
and had just moved in with XXX [male partner].  I came in from work and 
there were all these people in my house.  Couple hours into the evening 
there were all these drugs going around.  I took cannabis before and 
speed and acid.  Heard of Es but hadn’t tried them.  And then somebody 
brought out [heroin]…just a wee tiny bit.  I was terrified of needles and the 
girl just did it for me. I told her, ‘It’s not working,’ and about two seconds 
later, my head just fell and I fell asleep for about two days.  That was the 
heroin – I was going to try the Es but I thought I’d try this other stuff.” 
 
 Interviewer: “Were they injecting Es as well?” 
 
 Respondent: “They were injecting them, eating them.” 
 
 Interviewer: “How did it [heroin] make you feel?” 
 
Respondent: “It made me very sick.  Kept getting sick every 10 minutes.  
Doesn’t seem to annoy you - being sick.  Didn’t put me off.”  (134, female) 
 
A 27-year old male reported: 
 
“When I was 16, Es and Speed.  I noticed that I used to take more than 
anybody else…This drug came into town [Ballymena] that nobody knew 
anything about.  Must have been about eight years ago.  It was called 
skag.  I didn’t know it was heroin.  You smoked it in foil.  Tried that.  I was 
addicted to it probably, but I wasn’t getting any withdrawals.  Then 
somebody told me it was heroin.  Me being a diabetic, I had needles.  And 
I knew that you could inject it.  Somebody told me you mix it with citric 
acid.  So I didn’t need anybody to show me how to inject it.  I just mixed it 
up, cooked it and injected.”  (117) 
 
Other respondents reported that factors pertaining to the heroin market 
contributed to their initiation into heroin injection.  For example, some 
respondents were smoking heroin in countries where the purity of heroin was 
notably higher, e.g., Holland.  Upon their return to Northern Ireland, often with a 
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“habit,” they found that the purity of heroin was considerably weaker than that to 
which they were accustomed.  Smoking was perceived to be no longer an option 
because it was not cost-effective and because low purity heroin typically must be 
injected in order to feel the effects.  Changes in the heroin market in Northern 
Ireland also contributed to initiation into injection.  Some respondents had sought 
brown heroin in Dublin but were only able to access diamorphine.  Others 
recalled that brown heroin was not available in Ballymena for brief periods of time 
in 1996, 1998 and 1999.  Diamorphine was available during these periods; 
however, that substance cannot be smoked.  A 25-year old male reported:   
 
“I came home from XXX [club in County Antrim] and the only guy I could 
find had the diamorphine.  You can’t smoke it.  It was late at night and 
couldn’t find anyone else.  I had too much to drink – it was a late night.  All 
the guy had was diamorphine so I had a dig.” (010)     
 
A 30-year old male recalled a similar experience in Ballymena and like other 
heroin injectors perceived that injecting was more cost-effective:   
 
“There was diamorphine about.  No brown at all.  You can’t smoke 
diamorphine and there was the brother there of someone we knew.  He 
had injected before so he showed us.  He did me first then the other fella.  
We hadn’t injected before…When we were smoking we were spending 
100 pound a day on heroin.  Then it went to 25 pound a day when we 
started injecting.”  (026)   
 
A few respondents reported injecting for the first time in order to “comedown” 
from another drug.  A female had been using crack cocaine for nine years, after 
initiating crack use in England: 
 
“See the comedowns from crack?  Powerful.  You get really depressed.  
That’s why I used the gear [heroin] that first time. I heard it eased the 
comedown.  I was going mad, really really depressed.  Made a plan and 
took the train to Dublin.  You know Ballymun?  Wee lads lined up on the 
street with their bags of gear.  I couldn’t believe it.  I used to get it there 
[Dublin] and then bring it back here.”  
 
Interviewer: “So that was in 1995.  There was gear about in Ballymena in 
1995.  Why didn’t you score here?  Why did you go to Dublin?” 
 
Respondent: “It was cheaper for me to take the train down to Dublin and 
score there.  Here it was 35 pounds a bag and not that strong.” (034) 
 
Use of other stimulant drugs led others to inject heroin: 
 
“I was injecting amphetamine for 10-odd years then started injecting 
brown to bring me down after being up for 14 days without sleep.  Heroin 
knocks you out for a bit.  As it is insidious, before you know it you’ve got a 
raging heroin habit and the speed goes out the window.” (104)   
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Most respondents (82%) were injected by a male at initiation.  A total of 11% 
were injected initially by a female and 7% of the sample had injected themselves 
at initiation.  A male respondent reported that his first injection occurred in prison:   
 
“I was about 16 or 17, still a kid when I think about it.  I was buying DFs 
[Dihydrocodeine] and eating them everyday.  Then I woke up one day and 
didn’t have any.  I was sick as F*** and didn’t have a clue what was wrong 
with me.  Nobody warned me that I would end up rattling [withdrawal].  So 
I went and saw the guy I was buying DFs off.  He told me that skag would 
make me feel better and he had no DFs left.  Four hours later I was in a 
car in a car park in XXX [city in England].  It was arranged that me and my 
mate brought an ounce of heroin back to [N. Ireland].  We smoked it in the 
car.  I felt it go through me and felt better.  I had my first hit about a year 
later in jail.  I nicked a syringe from a nurse and got somebody to get me a 
lemon from the kitchen.  There were three of us.  I knew what to do [how 
to inject] from watching others.  It was my gear, so I went first.” (126) 
 
Some females recalled that males had expressed an interest in injecting them for 
the first time.  For example, a female had a male partner who had injected for 
several years.  They eventually separated during which time the female was 
offered “a dig” [injection] while visiting friends.  She initiated at that time when a 
male acquaintance injected her.  Later she reconciled with the male partner: 
 
“He said, ‘You’re a bitch – you let them hit you up [inject you] and you 
never let me hit you up.  Here let me show you how it’s really done.  Let 
me give you a proper hit so you know what it’s really like’.”  (148) 
 
 
Patterns of Injecting Drug Use  
 
Midway into the data collection, we began to collect information on the time 
between initiation and the “next hit.”  From those data, 63% of respondents 
injected a second time within 24 hours of their first injection.  However, a few 
individuals did not inject a second time until months or years later.  A female 
reported that she injected cocaine at initiation.  Her next injection occurred five 
years later when she injected Morphine Sulphate Tablets (MST).  Daily injecting 
occurred rather frequently for most respondents.  However, some reported 
“dabbling” [using infrequently] for several years during which they experienced 
few effects of withdrawal.        
 
The length of time since initiation into injection ranged from less than one year 
(i.e., respondents who had initiated injection within 11 months of the interview) to 
33 years.  Respondents had injected an average of 8.6 years (median=7; 
mode=7).  The number of injecting years did not differ significantly by gender 
(males=8.87 years; females=8.07 years).  On average, respondents who resided 
in the Eastern Board had injected for approximately two years longer (9.1 years) 
than respondents in the Northern Board (7.3 years).        
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A total of 61% of the sample had injected during the 24-hour period before the 
interview and during that episode, most had injected heroin.  In the 30 days prior 
to the interview, 40% had injected at least once a day.  With regards to the 
number of injections in the past 30 days (as opposed to the number of injection 
days), we were able to collect these data from 81 of the 90 respondents.  From 
that sub-group, the number of injections ranged from 1 to 180 during the 30-day 
period prior to the interview.  In all, there were 2,397 injections among 81 
respondents in a 30-day period.  The number of injections during the past 30 
days differed significantly across health boards.  Specifically, respondents in the 
Eastern Board reported injecting more than twice as much in the 30-day period 
(54 injections) compared to respondents in the Northern Board (24 injections).  
This finding might be explained by the fact that a higher number of respondents 
in the Northern Board were in treatment at the time of the interview (discussed 
later).     
   
Respondents who were not in contact with drug services at the time of the 
interview injected nearly twice as often in the 30-day period prior to the interview 
(mean=47 injections; median=30 injections; range=1 to 180 injections) than 
respondents in contact with services (mean=25 injections; median=23 injections; 
range=1 to 90 injections).  Among respondents who were not in contact with 
services at the time of the interview, 22% injected once a week or less, 
compared to 40% of respondents who were in contact with drug services.  
Moreover, respondents who were participating in a programme of substitute 
prescribing (i.e., Methadone or Subutex) were injecting considerably less often 
than before they participated in the programme.   Specifically, many of the 
methadone clients had reduced the frequency of injection from two or three times 
per day to a few times per month.  Similar findings were observed for the majority 
of respondents on Subutex.  A male had been prescribed Subutex for three 
months and had not injected until the day before the interview: 
 
 Interviewer: “Can you tell us why you think you had a dig yesterday?” 
 
Respondent: “I honestly can’t tell you.  I was going to buy cannabis.  Was 
up around [neighbourhood] and asked a couple of dealers if they had 
cannabis.  Didn’t have any.  So walking down and seen this heroin dealer.  
As soon as I seen him - first words out of my mouth were, ‘Any gear?’  I 
wasn’t even craving or thinking about it.  Just bought it, and then I had it in 
my hand and saying to myself, ‘I don’t want this.  What will I do with this 
here?’  Walked about for awhile looking for someone to sell it to because I 
didn’t want to take it and I knew it wouldn’t do anything for me with the 
Subutex.  Was going to take it back to the dealer but ended up coming 
back, cooking up and injecting it.  Didn’t really get much off it.”  (136)   
 
 
• Injecting patterns and type of drug 
 
A few respondents had injected one drug since initiation.  The majority of 
respondents, however, reported that they had injected more than one drug over 
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the injecting career.  A total of 97% had injected heroin (“brown” or Diamorphine) 
at some point.  Additionally, 67% had injected powder cocaine and 31% had 
injected crack cocaine.  Other drugs injected over the lifetime included 
amphetamine (45%), MDMA (18%), Morphine Sulphate Tablets (49%), Nubain 
(8%) and a host of other opiates.  Some had injected LSD and others reported 
injecting vodka, paracetamol and water.   
 
We observed significant differences between respondents from the Eastern and 
Northern Boards in terms of whether respondents had ever injected a particular 
drug.  That is, respondents residing in the Eastern Board were significantly more 
likely than respondents in the Northern Board to report injecting cocaine (83% 
compared to 50%), and amphetamine (71% compared to 25%).  No significant 
differences were noted for other categories of drugs.     
 
A total of 46% of the sample reported that they had smoked crack cocaine.  This 
figure is likely to be higher because in most interviews, we did not ask this 
question directly.  Some respondents did not enjoy the effects of crack at all: 
 
“It’s funny because like I did crack and it’s supposedly highly addictive.  
More addictive than smack.  I smoked it, felt the buzz, and I didn’t like the 
buzz at all.  I never touched it again at all.  I just wish I could do that with 
smack.” (109)   
  
We asked some respondents how they prepared crack cocaine for injection.  A 
male had first smoked crack cocaine in Northern Ireland in 1989: 
 
 “We started off smoking it.  We’d get cocaine and wash it up as crack.  
You see, you can buy crack or you can buy cocaine and wash it up.”  
 
Interviewer: “How would you wash it up?” 
 
Respondent: “Just a bit of ammonia, or you can use bicarbonate soda.  
Before it solidifies, I’d inject it.  At first I was smoking 100 pounds a day.  I 
was married then and I’d go into the bathroom, run the bath and have it 
stashed there.  I used it all the time, always trying to hide it [from his 
partner].” (029) 
 
The respondent continued to use crack for seven years, and eventually injected 
it.  He smoked heroin for one year “always after I used crack” but never injected 
heroin.     
 
No clear pattern emerged regarding the sequence of drugs that were injected, 
although 75% of respondents had initiated with heroin.  Two male respondents 
who were part of the same social network reported smoking heroin in 1994, using 
crack cocaine and cocaine powder between 1994 and 1996, injecting their first 
drug (an opiate) in 1996 and injecting heroin for the first time three years later.  
Their drug of choice, however, was amphetamine which they preferred to inject.        
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A 31-year old respondent was 14 when he first snorted cocaine, and reported 
being “addicted” to cocaine by the age of 16.  He smoked heroin for the first time 
when he was 18 and continued smoking for five years, before he injected heroin 
at the age of 23.  He subsequently injected cocaine and a host of other 
substances.  He reflected on this pattern: 
 
“See I’ve thought about it.  Used to be I didn’t like smackheads.  Then I 
became one.  Then I hated the injectors.  Low lifes, I thought.  Then I 
became one of them.  I’ve become the drug user I used to despise.”  (033)   
 
Respondents who had injected cocaine, crack cocaine, amphetamine or Nubain 
on a regular basis reported injecting more frequently than respondents who 
injected heroin.  For example, respondents who reported intravenous use of 
Nubain (for pain relief, the drug is usually injected into a muscle) reported that 
they had often injected the substance upwards of six times per day.  Some 
amphetamine users recalled injecting the drug four to five times daily.  Others 
reported that they had injected cocaine 10 to 15 times per day whereas others 
had injected every three hours.  Several respondents reported that they injected 
‘speedball” or “snowball,” a combination of heroin and cocaine.  A 33-year old 
male described the experience: 
 
 Interviewer: “So do you use equal amounts when you inject them?” 
 
Respondent: “Maybe a 30 pound bag [Belfast] – ¼ gram – and just a tiny 
bit of coke.  The needle fixation really kicks in on the coke.  You see, it’s a 
local anaesthetic so you don’t feel the needle.” 
 
Interviewer: “So when you use heroin, do you inject less often than when 
you inject coke?”   
 
Respondent: “Oh aye.  I might have two hits of gear [heroin] a day, but 
with coke you might have 50 to 60 a day.” 
 
 Interviewer: “50 or 60 injections, yeah?” 
 
Respondent: “Yeah. You can just keep the needle in your vein, inject, and 
then remove the syringe and fill another and replace it.  Do that loads of 
times with different syringes and all the while, you leave the needle in the 
vein.  Saves you from finding a vein each time.  You’d do that more with 
speed or coke than heroin.” (030). 
 
The respondent also noted that he generally did not inject cocaine.  When the 
opportunity arose to inject the drug, he would often inject large amounts of the 
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• Controlled use 
 
 Some respondents were able to “control” the frequency of injection in particular 
settings, or at particular stages of the drug career.  A 39-year old male who had 
been using heroin for seven years and injecting for three years told us that he 
purposely had not used the day of the interview in order to participate in the 
interview more fully.  We interviewed him around tea time that day and did not 
observe any visible effects of withdrawal.  He also had moved back into his 
parents’ home so that “other people [IDUs] would not call to the house.”   A few 
respondents reported that they had switched between injecting and smoking 
because smoking provided them with more control over their drug use (a few 
others told us that friends had resorted to smoking because of venous damage).   
Some managed to work in full-time employment, injecting after the work day had 
ended.  A 30-year old male had worked steadily since he first injected in 1998 or 
1999.  He never sought treatment because he thought it would interfere with his 
work and feared that his employer would learn of his drug use.  Another 
respondent who was employed full-time reported that although he injected heroin 
a few days each week, he smoked it during his lunch hours because he was 
better able to control his drug taking though this route of administration.  A male 
in full-time employment described: 
 
“I can tell you how many hits I’ve had [in the past 30 days].  I know that 
I’ve had five [injections] each week over the past four weeks.  That’s how I 
do it.  I maintain my habit with work.  My wages are set out to where if I 
wanted to I could afford to buy one bag every day of the week.”  
 
 Interviewer: “Can you work when you’re…?” 
 
Respondent: “Oh yeah, because my job is not strenuous at all.  Any job 
that I’ve had in the past when I haven’t been using – I’m not fit to work.” 
(110)         
 
A male reported that he worked for several years while using heroin: 
 
“I can function on the job and be a normal person so the whole quandary 
is why they can’t prescribe me diamorphine and let me get on with my life.  
Without it, I’m a burden to society which just gets me further depressed 
which requires more medication, more doctors’ resources.  I’ve always 
worked.” (104)    
 
 
• Injecting and social networks.  
 
A social network represents the nature and number of linkages among people 
within a particular subculture (Klovdahl, 1985; Williams and Johnson, 1993).  
Trotter (1995) concluded that an increasing number of studies have focused on 
the social networks of IDUs and the relationship between social networks and 
infectious disease.  The nature and characteristics of IDUs’ social networks can 
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contribute to or reduce the likelihood of the transmission of infectious disease, 
e.g., HIV, hepatitis C, and can affect treatment entry and retention.  Lovell (2002) 
described the linkages among IDUs:  respondents who inject drugs together are 
said to represent a sociometric network.  An IDU can be a member of more than 
one sociometric network, thus other IDUs in separate sociometric networks can 
be linked indirectly through the multiple membership of one IDU.  Such networks 
can serve as conduits for the spread of infectious disease but can also be a 
source for transmitting information about injecting behaviours and risks 
associated with those behaviours.  We observed several linkages between and 
among sociometric networks in our study.  Females, in particular, appeared to be 
vulnerable for infectious disease through these linkages.  For example, a female 
respondent noted that she was unattached to most other IDUs in her area.  She 
knew very few IDUs and reported “sharing” injection equipment with her male 
partner only.  A month before we interviewed her, we had conducted a separate 
interview with a close male associate of her male partner, who noted that he also 
routinely injected with the male partner.  We observed this pattern in several 
social networks in which a female partner reported using injection equipment 
from her male partner only.  That is, females tended to report injecting with one 
person only (often a male partner).  Their male partners, however, often were 
injecting with other people.  With regards to injection equipment, females tended 
to report that ‘I only share with him’.  However, the male partner’s linkages with 




Injecting Behaviours that Pose Risk for Infectious Disease 
 
 
• Frequency of loaning and borrowing injecting equipment (e.g., 
needles, syringes, filter, container, water, needle/syringe).  
 
Some long-term injectors without partners reported their preference to inject 
alone. Although there might be an increased risk for fatal overdose when one 
injects alone, the risk for infectious disease might be minimised if the injection 
equipment is new.  Although some research has suggested that recent initiates 
engage in more risk taking than more experienced injectors (Peters et al., 1998), 
we interviewed one male in his 20s who had first injected in 2003, the year he 
was interviewed.  He had never injected with another person and learned the 
mechanisms of injecting from safer injecting material that he located on an 
internet website.  He described how he would inject: 
 
“I score and get home as quick as I can.  Go to my room, lock all the 
doors.  I have a bottle of fresh water there.  I take out a spoon and I clean 
the spoon with an alcohol pad.  I empty the powder into the spoon and 
add citric acid to break down the heroin.  I add about 120 mls of water, 
cook it, stir it up, put the filter in there.  Suck the contents of the spoon into 
the needle.  I rotate my veins and look for a vein that hasn’t been heavily 
used before in my arms.  Put a tourniquet on, tighten it up.  Find a vein.  
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Put the needle in, wait for the blood to make sure I’ve found a vein, and I 
inject it.” (109).    
 
Many other respondents reported that they had injected with one or more 
respondents in the 30-day period prior to the interview.  At times, the cost of a 
drug contributed to the practice of injecting with another person.  That is, two or 
more respondents could contribute financially to the cost of the drug so that a 
larger amount of the drug could be purchased (see also, Koester, 1994).   
 
Although we were interested in the nature of and extent to which people 
borrowed or loaned used injection equipment, in most interviews we attempted to 
avoid the word “sharing.”  The phrase has different meanings among IDUs, and 
often lacks validity (Koester, 1994).2 Use of a single question on “sharing” tends 
to show lower percentages of “sharers” compared to multi-item questions that 
specifically address various injecting equipment and sources of contamination 
through injecting drug use (Hunter et al., 2000).  Initially, the interview guide 
included several questions that attempted to measure the number of times that 
respondents had engaged in certain behaviours in the past 30 days, e.g., 
injected with a needle that had been used by another injector, used a filter that 
had been used by another injector.  We found that these questions generated 
confusion during the interviews, particularly for respondents who had injected 
with different people during the 30-day period.  We concluded that these 
quantitative measures of risk lacked validity within our sample, thus we 
subsequently used a qualitative approach when asking about these behaviours.  
We found that in many interviews we had to “tease out” the extent of loaning and 
borrowing by discussing various injection settings, or by asking people to 
describe their recent injection episodes.    
  
Nearly all respondents had used a new needle and syringe during most injection 
episodes in the 30-day period before the interview.  When injecting with at least 
one other person, most respondents reported using a separate needle and 
syringe.  We observed some exceptions to this finding.  For example, many of 
the respondents who reported that they were positive for hepatitis C also stated 
that they had used another’s needle or syringe in the 30-day period prior to the 
interview.  Knowing that one had the virus appeared to increase the likelihood 
that s/he would inject with another’s used needle/syringe: 
 
Interviewer: “In the last 30 days, have you filled a syringe that somebody 
else had used, and then used it yourself?”   
 
 Respondent: “Yeah.”   
 
 Interviewer: “Did you clean it?” 
 
                                                 
2 We do note, however, that “sharing” is the term used in the collection of data from both the 
Northern Ireland needle exchanges and the Regional Drug Misuse Database.   
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Respondent: “It was already clean, I was told. The guy I borrowed it from I 
know him very well.  As far as I know he’s not positive for anything except 
for Hep C which I already have.” (115) 
 
A 26-year old male reported that he had used a new needle/syringe each time 
that he injected in the past 30 days: 
 
Interviewer: “So in the past 30 days, did you ever pass on the needle or 
syringe to someone else?” 
 
Respondent: “Yes, but I’ve always warned them – told them about the 
Hep.  Usually it’s someone else with Hep.  Their attitude is like, ‘Well I 
have Hep anyway.’  I always say to them, ‘Well, there’s many different 
strains of Hep and you might have one and I might have another.’ ” (110) 
 
The majority reported using one or more needle exchanges (discussed below) 
and appeared to be quite knowledgeable about the risk of contracting infectious 
diseases through injecting with someone else’s used needle/syringe.  Still 
though, particular circumstances and settings contributed to the likelihood that 
individuals would inject with needles/syringes that had been used previously by 
another injector:       
 
 Interviewer: “Has anyone used your syringe in the past 30 days?” 
 
Respondent: “No, but people have asked and I’ve told them about the Hep 
C. It’s up to them.  Just dying sick.  Even knowing I have it - people have 
used my syringes and needles.” (128) 
 
With regards to other injecting equipment, the data revealed that when two or 
more people injected together, they most often used the same filter, spoon/ 
stericup, and water despite using separate needles/syringes.  Again, withdrawal 
and limited availability of new equipment often led to this form of risk taking.  
Respondents reported that they had given their used filters to friends and 
acquaintances.  A female reported that she had used filters and spoons from 
others when she had been sick: 
 
“She said, ‘You know I’ve got some filters like, but I’ve got Hep C.’ And I 
went ahead and used it.” (133) 
 
A male respondent reported similar experiences: 
 
Respondent: “Actually in the last month I have used a filter [someone 
else’s filter] and I shouldn’t have.  But I was going to be sick the next 
morning.”  
 
Interviewer: “Did you ask him if he had Hep?”   
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Respondent: “Yeah, he said he didn’t the last time he was tested, but he 
could well have it now.”   
 
Interviewer:  “And you just went ahead?”   
 
Respondent: “Yeah, f*** it. I decontaminated the barrel.”   
 
Interviewer: “Still used the filter?”   
 
Respondent: “Oh aye.” (125)    
 
The data suggest that the number of spoons or stericups that were used during 
an injection episode appeared to depend on the number of bags that were 
bought and the number of people that would be injecting.  One bag shared 
among two or more people usually meant that one spoon or stericup was used.  
Two bags for three injectors usually meant that two spoons/stericups and two 
filters would be used.  A male respondent described: 
 
“If we score together and get a bag each, we just cook up separately.  But 
if we are going to split it, we throw it in the one spoon, cook it up, and use 
a clean spoon, clean water, new filter, and judge it by eye, you know 40-
50 mls each.  Split it like that. Hit it up.”  (105) 
 
We discussed this pattern with an outreach worker of the South Belfast Drug 
Outreach Team.  It was suggested that when two people have one bag of heroin, 
often they prefer to use one stericup or one spoon because it is easier to divide 
the drug when it is in liquid form and prepared for injection.  That is, the 
calibrations on the syringe make it easier to divide the drug equally.  Koester 
(1994) found a similar pattern in his 1988-1992 study of injectors in Denver.  In 
many ways the risk for infectious disease might be minimised if the needles are 
new, the filter has not been used previously, the spoon is clean or the stericup is 
new, and the water is clean.  Indeed, without specifically asking about this issue, 
some respondents clarified to us that the needles were new and were placed in 
the spoon at the same time.  Risk can be increased, however, when respondents 
come into contact with the blood of another or when individuals inject a second 
time.  A male respondent recalled that four months prior to the interview, he 
injected with five different people over a four-day period: 
 
“We all got needles out of the needle exchange, so everybody had a 
needle but we shared the spoon and the filters.  But we didn’t share the 
needles.  It’s because it’s a brand new needle and everybody’s sticking 
their brand new needles into the filter, so there couldn’t be anything on 
that needle.” 
 
The interviewer learned that the group injected a second time: 
 
Interviewer: “So even though everybody’s gouching [nodding off; sleepy 
state], would you use a fresh filter when you cooked up that second hit?” 
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Respondent: “No, we used the same one.  New needles though.”  (136)  
 
In this scenario, the filter was re-used among all injectors who were present.  The 
respondent appeared to believe that risk was minimised because new needles 
and syringes were used during the second injection.   
 
Respondents also reported the accidental use of another’s needle/syringe.  That 
is, two or more respondents injected and nodded off.  Upon awakening, they 
observed their two sets of works but could not recall whose was whose.  Some 
respondents reported that the situation had occurred “loads of times” (033).   
 
The findings suggest that several if not most respondents lack knowledge about 
injection equipment (e.g., spoon/stericup, filters, water) that can serve as 
conduits for the transmission of disease (Hagan et al., 2001).  Alternatively, the 
majority of respondents had knowledge regarding the importance of using new 
and separate needles/syringes.  Two male amphetamine injectors reported using 
separate needles/syringes each time they injected together: 
 
 Interviewer: “So what about filters, water and spoons?” 
 
 Respondent: “We share all that.”  (012) 
 
 Interviewer: “So why do you use separate needles and share filters?” 
 
Respondent: “Yeah, my doctor told me it was the same thing – sharing 
filters is the same as sharing needles.”  (013) 
 
 Respondent: “[Addresses interviewer] Is it the same thing?”  (012) 
 
In addition to feelings of withdrawal or the anticipation of withdrawal, respondents 
reported other reasons for using the needle/syringe of another.  A male 
respondent had lived in England for a time, and had injected there: 
 
Interviewer: “Did you ever use works from someone else?” 
 
Respondent: “Oh yeah.” 
 
Interviewer: “Like on Sundays when the chemist was closed?” 
 
Respondent: “No, the exchanges were open on Sundays.  Seven days a 
week.” 
 
Interviewer: “And did you live close to an exchange?” 
 
Respondent: “Yeah, close enough.” 
 
Interviewer: “How many pins [needles] did they give out?” 
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Respondent: “60 – we’ve a lot of users over there.” 
 
Interviewer: “So help me with this one.  Why would you use someone 
else’s?” 
 
Respondent: “Laziness. You got your gear [and] want to get back to the 
house.  You just can’t be bothered taking an hour out and getting to the 
exchange and back.  You don’t want to leave the house.” (033) 
 
A minority of respondents also reported that a weariness of frequent visits to an 
exchange led at times to a lackadaisical attitude with regards to obtaining new 
equipment.  Despite knowing the possible health consequences, obtaining new 
injecting equipment prior to scoring, at times was just not feasible.  For others, 
anxiety about carrying a “sin bin” to another location resulted in an alternative 
method of transporting injection equipment, which in turn created confusion:   
 
“I keep my pins in the sin bin.  But sometimes in a friend’s house we’ve 
just pulled them out of a plastic bag and sometimes they all mix.  (122, 
female) 
 
Some respondents reported that they borrowed and loaned equipment with one 
other person only.  They perceived that the other person was “safe” or “clean” 
(i.e., did not have hepatitis C or HIV).  Several noted, “I know [she] he is safe,” 
but the “evidence” for this belief generally was based solely on the relationship 
between the respondent and the other person, e.g., partners, siblings, close 
friends.  This type of risk still can contribute to the spread of infectious disease, 
particularly in places where the prevalence of hepatitis C is high (Valente and 
Vlahov, 2001).           
 
 
• Dependency on others to inject. 
 
Several female respondents relied on males to inject them, despite having 
lengthy injection careers.  Some women had never learned how to inject 
themselves, whereas others were uncomfortable injecting themselves.  Women 
tend to have smaller veins than men (Kral et al., 1999) and consistent with this 
sex difference, we observed that females were more likely than males to report 
skin-popping, largely because “I’ve no veins.  Never had them” (014).  A 25-year 
old female had been injecting for four years but rarely injected herself:   
 
“I was shitting myself and even now I don’t feel confident shooting 
up…there’s usually somebody else there to dig me.  My arms are F***ed.  
I’ve used my groin three times recently and a [male] marked it [site in the 
groin area] with a pen. I would skin pop when I’m on my own.  It’s such a 
pain getting a vein.  I lie under a sun bed to heat my body up.” (122).     
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For thirty years, one female had relied on someone else to inject her: 
 
“Somebody’s always done it [injected me]. I never had any veins.  Got the 
artery once and that frightened the shite out of me…It was always like a 
guy would say, ‘I’ll do it, ‘I’ll do it.’ I could hit [inject] anybody up no matter 
how bad their veins are.  I just don’t like hitting me up.  Done my feet a few 
times, but that was extreme.  And I’ve done my neck.”  (147) 
 
Some male injectors with poor veins from injecting also relied on other 
respondents to inject them.  We noted however, that the males had a history of 
injecting themselves most of the time whereas many females had never done so.    
 
 
• Sources for obtaining needles/syringes – past and present.   
 
The first pharmacy-based needle exchange schemes were implemented in 
Northern Ireland in 2001.  Several respondents recalled the difficulty of obtaining 
new needles and syringes prior to this provision.  During that time, some IDUs 
travelled to Dublin or parts of England to collect dozens of needles and bring the 
supply back to Northern Ireland.  In some regions of Northern Ireland, needles 
and syringes were sold for one pound sterling and could be purchased from a 
local dealer.  Some respondents recalled periods of scarcity whereby needles 
were sold on the street for five pounds each.  A few Ballymena respondents 
reported purchasing drugs from the money that they earned from selling needles.  
Other respondents reported that they eventually found a chemist – often located 
far from their residence – who would sell needles and syringes although in 
several instances the chemist eventually stopped selling.   A number of IDUs 
relied on friends or acquaintances who were diabetic and a few respondents had 
diabetes which afforded them a constant supply, albeit sometimes not the 
preferred size.  Despite these sources, needles and syringes were extremely 
difficult to obtain for the majority of respondents who were injecting prior to the 
implementation of the exchanges.  Needles were valuable commodities and 
consequently would be used for several injections.  A male who injected first in 
the mid-1990s reported: 
 
“There was loads of sharing back then.  We were all at it because needles 
were hard to come by…Just by luck I knew a diabetic and he was an 
injector as well.  We used to get needles from him.  I was going out with a 
girl from XXX [town located near Belfast].  Was there one day and by 
chance called to a chemist who sold me the needles.  [Paid] £22 for 100.  I 
used to get them there and bring them to XXX [place of residence] where 
I’d give them to some friends and sell them to others for a pound or two.”  
(028)   
 
Several respondents from the Northern Board recalled the work of one 
community worker who in the late 1990s began to distribute new needles to local 
injectors.  The majority of respondents from the area reported that several 
injectors had benefited from the distribution:   
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“If it wasn’t for him, this town would be a mess.”  (037, male) 
 
“He would have brought you needles anytime.  12:00 at night.  He’d been 
out for you.”  (137) 
 
Elsewhere in Northern Ireland, respondents recalled the constant search for new 
needles: 
 
“See the sharing that went on.  I remember knocking on doors at 2.00 in 
the morning trying to get a needle, just because you knew that person 
used [injected].  You’d keep a needle for weeks – file it down to make it 
work better.” (male, Western Board) 
 
Several other respondents reported methods that were used to sharpen needles, 
e.g., the use of matchbox edges.  One recalled using superglue to repair broken 
needles.  Still though, respondents experienced great difficulty in their attempts 
to inject with blunt needles:     
 
“I was living up in Antrim and there was a chemist in Antrim who sold pins.  
You’d use them 10 times, and hold it against the wall just to get it in.” 
(144) 
 
Koester (1994: 289) noted that “used needles clog and break, and plungers wear 
out.”  He also observed that injecting is easier with new needles, particularly 
among IDUs whose veins have been damaged.       
 
Some respondents experienced difficulty in accessing new needles/syringes 
despite the implementation of the exchanges.  A 34-year old female respondent 
described a recent transaction of works: 
 
“I had to give him a needle.  He’s very lucky.  It’s Easter [exchange closed] 
and I got these off a dealer.  Someone was telling me earlier, when you go 
to the needle exchange and they ask you, ‘Do you share?’  Tell them you 
only share on bank holidays - whenever you can’t get needles.  I mean, 
how can an exchange close for two or three days?”  (133)     
 
A young male respondent had first injected about seven months before the 
interview.  He had just recently started to use the exchange: 
 
 Interviewer: “So where were you getting the needles before then?” 
 
 Respondent: “From the chemist [purchase].” 
 
 Interviewer: “And would you clean them?” 
 
Respondent: “Aye, just with a tissue or a cloth, or my sleeve. Then rinse 
with water…We were all using the same needle.”   
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The interviewer learned also that he might have been injecting incorrectly: 
 
Interviewer: “From the looks of it, you’ve been going against your blood 
flow.” 
 
Respondent: “Aye, I’ve been going down and all.” 
 
Interviewer: “You’ve been going down.  Are you aware now that you 
should be going up?” 
 
 Respondent: “Aye, that’s what they [drug service] were saying.”  (131) 
 
 
• Access to and utilisation of needle exchanges.   
 
The vast majority of respondents had utilised one or more needle exchanges in 
Northern Ireland (one respondent residing in Belfast did not know about the 
exchanges until we interviewed her). Some, however, preferred to purchase 
needles from pharmacies.  Others accessed needles/syringes from both sources 
and some relied exclusively on other respondents as their source of injecting 
equipment: 
 
“See that needle exchange on XXX [street name]?  I get my prescription 
from there and I’m scared to go in there and ask for needles.  I’m scared 
they will cancel my prescription so I’ve been using blunt needles and all… 
I’ve never used it once in the whole year.  I’ve relied on other people to get 
me them.  Been a nightmare.  Means I’ve been using old blunt, wrecked 
ones.” (120)   
 
In most instances, respondents tended to report that pharmacy staff were friendly 
and non-judgemental.  Clearly, some pharmacy staff had developed good 
relationships with needle exchange clients: 
 
“See when you use this stuff [heroin], I really feel low all the time.  When I 
go into the [pharmacy-based exchange in the Eastern Board] there are a 
couple ladies that work there and the gentleman with the grey hair.  They 
really treat you like a person.  Unbelievably like.  I go in there feeling like 
crap – like these people looking down at me.  I’m coming in there, not 
even spending any money.  I’m getting needles to use hard drugs and 
these people are greeting me with smiling faces.  I almost feel like getting 
these ladies Christmas presents.” (110)  
 
However, several respondents were very critical of one exchange in particular, 
citing the rudeness of the staff and the perception that staff “looked down” upon 
them: 
 
“They look down at you and they keep you waiting half the day.  They treat 
you like you are the scum of the earth.” (006) 
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“You have to ask for a carry bag,  I usually bring one with me – that cloth 
bag over there – and use that.  I don’t think I’ll go back there.  I don’t like 
it.”  (036) 
 
Interviewer: “So have you ever said anything to staff there who treat you 
like that?” 
 
Respondent: “Well, you’re the one who has to be kind.  We have to be 
pleasant because we depend on the service.”  
 
Many respondents eventually stopped using the exchange and attempted to 
obtain needles from another exchange even though it was located farther from 
their homes.   
 
Elsewhere, a few respondents reported being barred from using an exchange 
because: 
 
“He knew I was leaving back empty boxes.  Sometimes I wouldn’t pick up 
more because I was doing something else.  Then I’d call later and ask for 
a starter pack.  He thought I was putting them in the bin or something.  
Wouldn’t serve me.  Just started buying the insulin syringes up the street.” 
(105)    
 
At times, returning the used needles was just not feasible: 
 
“Say you’ve just scored.  You’re not going to go all the way back home to 
get your dirty needles and then all the way back to get the new pins.  
You’re going to use the dirty needles, because they only give you two 
[without returning used equipment].  It depends on how long you’ve been 
on heroin.  If you’ve no veins, well two’s no good.  They call it a starter 
pack.  It’s more like a disabled pack.”  (104) 
 
Although some respondents were not concerned over the lack of privacy in 
exchanges, several other respondents voiced criticism: 
 
“You have to wait until everyone is out of the queue.  They stare at you 
and there’s no private booth.  Everyone knows what’s in that bag.  I try 
and go in the side door – there’s cameras outside.”  
 
 Interviewer: “Why are there cameras?” 
 
 Respondent: “I don’t know.  Maybe for the drug squad.” (005)  
 
A few others reported that they refused to utilise certain exchanges because of 
perceived police surveillance.   
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A 26-year old male mentioned the “embarrassment” of being an injector.  He 
reported that he once waited two hours outside the exchange in hopes of finding 
someone to utilise the exchange for him: 
 
“You’d just wish the ground would swallow you up.  [When inside the 
exchange] I’d wait five to ten minutes for the place to empty.  Sometimes I 
send her [non-IDU female partner] in for me…Sometimes it’s OK, but it’s 
pot luck whether you’re going to get it easy or not.”  (011)   
  
The respondent rarely returned his needles/syringes to the exchange because “I 
hate going in that place.  Embarrassing.”  A male respondent from another board 
area reported similar concerns: 
 
“I can’t get needles.  I’ll go in with him but I stand back and he gets them 
for the both of us.” 
 
 Interviewer: “You go into the chemist, but you won’t ask for them?” 
 
 Respondent: “Yeah, it’s embarrassing.  I’m just too embarrassed.”  (012) 
 
A female reported: 
 
“They have that book there.  You know, the one that you put your initials 
down.  The book sits right out in the open.  I heard that certain people go 
in and look in the book sitting there.  Look at the initials trying to find out 
who is using the exchange.  I find the whole thing very stressful.  I use it, 
but it’s all very stressful.”  (036) 
 
“Secondary exchange” refers to injecting equipment accessed by IDUs from a 
needle exchange who in turn distribute the equipment to other IDUs who “cannot 
or choose not to attend” needle exchange schemes (Bastos and Strathdee, 
2000: 1773).   In the present study, some female respondents relied on male 
partners to access equipment from the exchanges.  A 26-year old female had 
injected heroin, amphetamine and MSTs during the 30 days prior to the 
interview. In all she had injected approximately 51 times during the 30-day 
period, but had visited the exchange on two occasions only.  She relied on her 
male partner to provide her with equipment during the other injecting episodes.  
Another female recalled: 
 
“I was getting people to get them [needles] for me for a long time.  My 
initials are probably found on that list maybe 10, 12 times…When 
welfare’s involved, I’m really careful.  I mean careful – really terrified 
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• Residence and location of exchanges. 
 
The data indicate that the distance between the residence of the respondent and 
the nearest exchange created a number of problems for respondents who lived 
too far to walk to an exchange.  Taxi and bus fares were costly for people who 
had no access to private transport.  A 19-year old male was living about 20 miles 
from the nearest exchange.  He visited the exchange when he scored in the 
area.  He reported that he needed to organise these trips very carefully.  His 
friend (also an IDU) is employed and after leaving work in the late afternoon, the 
friend would collect him for the journey to the exchange:   
 
“[Several times] by the time he gets off work and we get to XXX [town], the 
place [exchange] is closed.” (005).   
 
A few respondents from Catholic areas in Ballymena noted that they avoided the 
exchange in Harryville because of the loyalist presence in the area:  
 
“I would use both [exchanges] but I’ve been chased from Harryville a 
couple of times ‘cause I’m a Catholic and this town is small.  I know a load 
of people that have been chased by the blokes hanging around that area.”  
(126)   
 
Some respondents who were maintained on substitute prescribing but still were 
injecting (although considerably less so) obtained needles from the same 
pharmacy from where they collected their prescription.  Most individuals who 
accessed these two services from the same chemist were unconcerned.  
However, a few reported problems in particular pharmacies: 
 
Interviewer: “Does the chemist ever say anything?  That you are getting 
needles and Subutex as well?” 
 
Respondent:  “Yeah, XXX [name of staff person in pharmacy] said once, 
‘I’ll have to tell XXX [drug agency] about this.” (012) 
 
This experience caused him and others considerable anxiety, largely because 
they believed that Subutex was a positive experience for them and they feared 
that they would be removed from the substitute prescribing programme.     
 
Within some social networks, rumours often circulated with regards to 
confidentiality in pharmacy-based exchanges: 
 
“I heard last week that the doctors want to know if the Subutex ones are 
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• Restrictions on the number of needles distributed through exchange 
schemes. 
 
In several exchanges, a starter pack included five needles whereas an exchange 
with a return supply included between 10 and 20 needles (the number appeared 
to differ across sites).  Capping the number of needles during exchange 
transactions created problems for most respondents.  A female from Belfast 
explained:   
 
“But see the holidays?  At Christmas they were shutting for two days and 
we had enough for two days, and they shut for another two days, and we 
were working through the box a third time.  Picking the best [needles] the 
third time around.  If they don’t allow you take extras, it’s difficult.  I asked 
the guy [chemist] for an extra pack over Christmas – one each over 
Christmas.  He won’t allow you any extra.” (129)   
 
Additionally, many respondents reported venous damage, making injection more 
difficult.  A 30-year old male who first injected five to six years before the 
interview reported that he often needed up to five needles for one injection.   The 
exchange he used distributed 20 needles with a return of the same.  Twenty 
needles allowed him to inject between four and five times, after which he would 
return to the exchange for more.  At the time of the interview, he was residing 
approximately six miles from the nearest exchange and at the conclusion of the 
interview, the interviewer drove him to the exchange.  Another male reported 
similar problems: 
 
“And if you don’t take your old ones back they’ll only give you two from the 
needle exchange.  Somebody like me who finds it hard to get veins, I need 
at least 20 needles to find a vein.  Two are useless.  And that’s from a 
needle exchange.”  (104)   
 
A 26-year old male had been injecting for five years: 
 
“I have extreme problems getting veins.  I’m not exaggerating – 
sometimes I’m poking for two or three hours before I finally get it into a 
vein.  Other times I poke for two or three hours and there’s too much blood 
so I stick it into a muscle.”  (110)    
 
 
• Quality of injection equipment obtained from exchanges. 
 
Several respondents reported that a needle sourced from an exchange had 
broken once it penetrated the skin.  Some exchange needles were described as 
“barbed” or shaped like a small fish hook: 
 
 “It’s not a problem going in, but you feel it coming out.” (104) 
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Apparently there was a change in the type of needle distributed from the 
exchanges but some respondents reported that their experience with faulty 
needles occurred since the change had occurred.  One respondent reported 
attending hospital after a part of a needle had broken in his arm.  While in 
casualty, he was told to return the next day at which point it was discovered that 
the needle part had lodged near his lung where it remained on the day of the 
interview.  If parts of a broken needle cannot be removed by the individual, 
immediate medical intervention, e.g., surgery, is needed (Norfolk and Gray, 
2003), which was not provided to the respondent.  Some respondents reported 
that they no longer used the exchanges because of the perceived poor quality of 
the needles.  A 19-year old male reported: 
 
“Whoever made the decision about the needles – they must have thought, 
‘They’re only for skag heads – give them the cheapest ones.’ ” (005)    
 
Although hardened veins also can contribute to needle breaking (Norfolk and 
Gray, 2003), the respondents in the present study mentioned that breaking 
occurred only with needles sourced through the exchanges.    
 
Several respondents reported using the filters supplied by the exchanges, 
although through ritual, some continued to use cigarette filters. The majority of 
respondents reported problems with stericups, noting that they tip or melt easily 
resulting in the loss of drugs or burned fingers.  Additionally, some respondents 
reported that the stericups cannot be heated for very long.  New stericup holders 
have now been developed by exchange distribution companies in England 
although it is unknown whether they are available in Northern Ireland.  It is likely 
that some respondents will continue to use spoons rather than stericups because 
of ritual; using a favourite spoon was reported by some injectors.     
 
 
Saving filters for re-use.  
 
Approximately half of the sample reported that they had saved used filters in the 
event that they were subsequently unable to obtain drugs.  Used filters would 
then be heated with water and then injected.  This practice has been observed 
elsewhere (Bennett et al., 2000).  Risk for HIV, hepatitis B and C would be 
minimised for individuals who use their own filters and who inject solely on their 
own.  A female reported that she often kept filters after she injected heroin: 
 
“When it comes to desperation, and you’re running out, everything’s kept:  
powder from the spoon, filters, the lot.”  (128) 
 
Some respondents saved their filters but never used them.  Others used them all 
the time.  A female reported that she and her male partner would split a bag of 
heroin nearly every day. They used one filter between them, which was saved, 
after which she would inject from the used filter the next morning.  The male 
partner rarely used the saved filter.  She explained:   
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Respondent:“I would do them up.  I would tend to be a greedy wee git.  
And if I went out and done all the running [i.e., scored], and done this and 
done that, I would normally take the filter.”   
 
Interviewer: “Does that cause arguments between you?” 
 
Respondent: “Yeah it would.” (112)  
 
Some respondents reported that they had obtained used filters from another 
person: 
 
“I just remembered. I did use this guy’s filters a couple of weeks ago.  He 
had no gear left but he gave me six [used] filters to cook up.  He’s a dealer 





“Flushing” is a behaviour that involves multiple injections in the same site during 
the same injection episode.  The substance is injected, the needle is withdrawn 
and then re-injected several times.  The process differs from “registering” in 
which blood that fills the syringe is indicative that the individual has “found” a 
vein.  Flushing can contribute to the spread of infectious disease (Abdala et al., 
2004) and can damage veins.   
 
We asked 59 of the respondents to describe the behaviour of flushing and 
whether they flushed regularly.  Of the 59 respondents, 46% reported that they 
flushed.  Some users reported that they flushed to ensure that all drug residue 
was injected.  Other IDUs disputed this reasoning arguing that “it doesn’t do 
anything for me” (116) or that flushing might be required for 2 ml needle/syringes 
only.  Respondents reported that flushing occurred through habit or because they 
enjoyed the feeling and ritual of injection.  Some described it in sexual terms (“It’s 
like masturbating with a needle” 001; “There’s definitely something sexual about 
it” 104).  A female respondent described her preference for flushing:   
 
Interviewer: “Flushing – have you…?” 
 
Respondent: “I love flushing.  I do it deliberately.  I’d do it with water.  I’d 
sit with the needle in my leg and watch blood coming in.  Shooh.” (128) 
 
Interviewer: “How many times would you draw back?”   
 
Respondent: “All depends on the vein.  Loads of times. I love it.” 
 
Interviewer: “Like 10 times?” 
 
Respondent: “Oh God, aye.”   
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Interviewer: “What’s the longest time you’ve seen yourself flushing?” 
 
Interviewer: “Teasing yourself?” 
 
Respondent: “Exactly, teasing myself…’Cause I know the anticipation’s 
there.  It’s not the hit, it’s the anticipation, the thrill.  It’s like teasing a 
bloke.  You know the whole thrill is the chase.”  (128)   
 
A number of respondents described what they perceived to be a fascination with 
needles and injecting generally.  A 38-year old female reported:  
 
“I must flush six times [per injection episode].  I just have to make sure it 
[the drug] all goes in.  I love to flush.  He doesn’t, but I do.” 
 
 Interviewer: “So is it a needle fixation?” 
 
 Respondent: “Oh aye.  The needles.  I just love to see one coming.”  (034)   
 
One male respondent noted that his love of injecting was his major problem: 
 
“I’ve got loads of addictions.  One’s alcohol, another’s Nubain.  But the 
third is the needle.  I am addicted to needles – love the feeling.  I told them 
at [drug service] and they didn’t understand.  I’d say if I could stop the 
needle fixation, I’d stop the Nubain.  When I’m waiting for something 
[some drug to inject] I think I could inject the water.  I don’t know what it is, 
but I love the needles.  I get cravings for jagging.”  (016) 
 
Some respondents reported that for them, flushing depended on the type of drug 
they were injecting: 
 
 Interviewer: “What does the term flushing mean to you?” 
 
Respondent: “Push it in a few times to make sure you got all the gear into 
your arm.” 
 
 Interviewer: “Would you flush?” 
 
 Respondent: “Yeah.” 
 
 Interviewer: “About how many times would you pull back?” 
 
 Respondent: “Gear – three to four.” 
 
 Interviewer: “Would it change if you were injecting a different drug?” 
 
 Respondent: “Oh yes, Speed – I’d flush until the cows come home.”   
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Interviewer: “And do you reckon it pumps the drug around your body 
more?” 
 
Respondent: “Not particularly, I just like doing it.  I’ve always been a 
needle junkie.”  (115) 
 
 
Exposure to other injectors in “high risk” areas  
 
The data indicate considerable exposure to other injectors from “high risk” areas.  
We defined “high risk” areas as those 1) in which large numbers of people inject 
and where research has found a high seroprevalence of infectious disease 
among IDUs, or 2) a prison or jail in which large numbers of injectors are housed 
and where research has documented high prevalence of hepatitis C or HIV 
among IDUs in the facility.  Using this definition, 51% of the sample were 
exposed to one or more of these “high risk” areas.  For example, several 
respondents had resided or visited, and injected with IDUs from Glasgow, 
Edinburgh, London or Dublin.  Others had served time in jail or prison in 
Scotland, England or in Mount Joy prison in the south of Ireland.  Respondents 
residing in the Eastern Board were significantly more likely than respondents 
residing in the Northern Board to report injecting in these high risk settings 
(Eastern Board=68%; Northern Board=19%).  
       
A male respondent recalled an experience in Mount Joy prison:   
 
“A syringe was being passed about and I nearly shit because the guy in 
my cell had the syringe.  I thought he meant it had been used eight times 
but it had been in the wing for eight days.” (126)    
 
Some respondents had been in prison in Northern Ireland although very few 
reported injecting in those settings.  A female had been on Subutex for three 
months when she was sentenced to Maghaberry for failing to pay fines: 
 
“I told them to ring [my] opiate nurse.  Told them I was on the Subutex.  
That was the first day.  Second day I started to feel sick and begged them 
to contact [opiate nurse].  Gave them the number and all.  I asked for a 
doctor.  The last day they came to get me and told me I could go.  They 
[prison officers] said, ‘So do you want that doctor now?’  Three days 
without my Subutex.”   
 
A male respondent reported being in a Northern Ireland prison before he was on 
Methadone maintenance: 
 
Interviewer: “So what did they give you in prison? Anything to help with the 
sickness?” 
 
Respondent: “Yeah.  Gave me two paracetamol and Gaviscon and told 
me to sort myself out.”  (035) 
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Others were given diazepam and DFs and reduced over a two-week period.  A 
31-year old described the experience of his friend who was on Methadone 
maintenance before incarceration and spent three or four days in prison because 
of unpaid fines: 
 
“They wouldn’t give him Methadone [in prison] and there he was, back [in 
detox] after he got out.” (028)   
 
 
Police practices and risk 
 
We found considerable evidence, particularly in the Northern Board area that 
police practices contributed to risk behaviours for infectious disease among 
IDUs.  Within that board area, several respondents reported having needles 
confiscated, with threats of being charged for possessing needles that were 
tainted with drug residue.  For example, a 19-year old male had a needle in his 
possession and the police confiscated it.  They examined it “but there was no 
Class A drugs on it.”  He recalled that he was not charged with drug possession 
but was fined £150 for possessing the needle.  His friend noted that, “You need 
to have the sin bin with you all the time” (004) but the 19-year old noted that, 
“They still hassle you.”  Another male reported: 
 
Respondent:“If you’ve got the black box, they [police] can’t do anything 
about it.” 
 
Interviewer: “What do the police do when they find a needle on someone 
who does not have the black box?” 
 
Respondent: “They’d charge you with possession if they found even a 
trace of heroin in.  They look down upon us.  You’re walking up the street, 
and they stalk you.  There’s an entry right there but they have to search 
you on the street [in view of passers-by].  It’s humiliating.” (006) 
 
A 31-year old male from the Northern Board reported: 
 
Respondent:“I was walking up the XXX [street name] and they [police] 
stopped me.  I had one syringe on me – clean.  And one spoon – not 
clean.  They stopped me and confiscated them.  Said in court that they 
seen me leaving the home of a known drug dealer.  That wasn’t true at all 
but they had to find some way to justify stopping me.  They found traces of 
heroin on the spoon.  Only traces.  Such a tiny amount.  They did me for 
possession of heroin.  150 pound fine I got.”   
 
Interviewer: “When was that? Was that before or after the needle 
exchanges were open?” 
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Respondent: “Oh the needle exchange was open alright.  But the spoon 
and syringe were not in a sin bin.”  (028)   
 
A respondent with diabetes reported that the police in Ballymena searched him 
on a Saturday afternoon in the middle of the town centre. The police confiscated 
his insulin syringes and placed them in full view of passers-by.   
 
Females were not exempt from public searches: 
 
“Got me once near the exchange.  Made me take my socks and shoes off 
– pissing rain so it was.  Right in the middle of the street, made me take 
off my socks and shoes.  Tried to search me there and then.” (034) 
 
Recent data collected from the pharmacy-based needle exchanges showed that 
the percentage of needles returned to exchanges was significantly lower in the 
Northern Board (44%) than in the Eastern (72%) and Western Board (72%) 
(Drug and Alcohol Information and Research Unit, 2004: 2).  Based on the 
findings presented herein, police practices in the Northern Board might have 
contributed to the lower rate of return in that board area.    
 
Similar interactions with police were reported by Belfast respondents, although to 
a lesser extent.  One Belfast male reported that he was stopped by police while 
heading to a needle exchange.  He was carrying the black sin bin which 
contained used equipment: 
 
Respondent:” They asked me where I was going with it.  I told them where 
I was going [i.e., to the exchange] and they took it off me.” 
 
 Interviewer: “Why did they take it off you?” 
 
 Respondent: “Evidence.” 
 
 Interviewer: “Evidence for what?” 
 
 Respondent: “I don’t know – fingerprints, traces, whatever.” 
 
The respondent was searched on across from the needle exchange.  No illicit 
drugs were found by police.     
 
These police practices contributed to respondents’ re-use of injecting equipment 
– either their own or someone else’s.  Other respondents were hesitant to return 
their used equipment to the exchanges because they feared police intervention.  
Returning to the exchange without used equipment, in turn meant that a smaller 
number of new needles could be accessed because of the cap on needle/syringe 
supply without a return.  Although some respondents had never been stopped by 
the police, news of police practices involving injecting equipment travelled quickly 
through networks of injectors.    
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Respondents described how the label of “drug user” provoked further searches 
by police:   
 
Respondent:” Searched me loads of times.  Trousers down and all.  
There’s mates who they got on the ground, choking them saying, ‘Don’t 
swallow it.’ I was in the bus station once getting a timetable for me mum.  
Came out and there they were.  Searched me right there in front of the 
bus station.  Said I was acting suspicious.”   
 
 Interviewer: “Why did they think you were acting suspicious?” 
 
Respondent: “Because I’m a junkie.  Everybody suspects the junkie.  They 
got nothing on me that day.  Not a trace.  Real humiliating though.”  (035) 
 
Some respondents who were told by police that they would be prosecuted for 
possession resulting from traces of a drug on injection equipment, never heard 




Alcohol and Benzodiazepines  
 
A total of 39% of respondents had consumed no alcohol during the 30-day period 
prior to the interview.  Additionally, 37% had consumed small amounts of alcohol, 
i.e., a few drinks, during the same time period.  However, several recalled that 
they drank quite frequently prior to using heroin.  Some respondents on 
substitute prescribing, Subutex in particular, reported that they were drinking 
more frequently because they were using heroin less often, or abstaining from 
heroin altogether.  Overall, however, we interviewed very few frequent drinkers in 
the study.  There were some notable exceptions, e.g., a young male who at the 
time of the interview was injecting morphine and benzodiazepine and drinking 
alcohol every day, beginning each morning.        
 
A number of respondents were consuming benzodiazepines on a daily basis.  A 
total of 37% were in receipt of a prescription for diazepam whereas others 
purchased them from street or Internet sources (which often differed in 
appearance from prescribed benzodiazepines).  Still others obtained them at no 
cost from partners, relatives, or friends.  Some IDUs had been prescribed the 
drugs for years, long before they ever injected.  For example a 21-year old male 
had been taking benzodiazepines since the age of 12 and reported having a 
long-term “habit” (021).  Some respondents had knowledge of the consequences 
of long-term use of benzodiazepines.  At the time of the interview a male 
respondent was taking two 5 mg diazepam per day: 
 
“They are dear now.  £1.50 for each yellow, so that’s £3.00 a day for me.  
Price has gone up.  Funny – the effect of the yellows.  Valium’s supposed 
to calm you down.  But after a while you get the same panic that it was 
supposed to take care of.”  (025)   
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Others had begun using diazepam while participating in other drug scenes.  For 
example, one reported that she had first used diazepam after leaving a club and 
“coming down” from Ecstasy (105).  A female reported that she had been 
prescribed Librium and that “I didn’t even know they were benzos” (132).    
 
Some people acknowledged dual dependence on their drug of choice and 
benzodiazepines: 
 
Respondent:” Every time I mentioned [Consultant Psychiatrist’s] name, my 
doctor wanted to try and help us get off drugs.  God knows how many 
DHCs and diazees [we were prescribed and took] over four years.  Our 
habits got worse.  We were addicted to three things instead of one.  And I 
got down on my hands and knees, said, ‘Look, I’m begging you.  I really 
need to see [Consultant Psychiatrist].”   
 
Interviewer: “You literally got down on your hands and knees?” 
 
Respondent: “Yes, hands and knees.  I was crying and said, ‘Please get 
[Consultant Psychiatrist].  And outside four days I was in [in-patient detox 
unit].”   (134)    
 
Many respondents had no knowledge at all regarding the dangers of 
benzodiazepine withdrawal although some had experienced lengthy withdrawal 
periods characterised by severe effects:    
 
“At least with gear, you know the end is in sight.  You feel like shit but 
there’s an end in sight.  With benzos, it’s months and months, and it’s 
much more subtle.  Things like, you don’t sleep properly, nightmares, day 
trembling, suicidal thoughts.  I never really felt depressed [except] when 
coming off the benzos. I had suicidal thoughts. It scared me.  Even still 





Sexual activity was rare among many long-term IDUs who had a partner who 
was also an IDU.  Of this group, many reported that they had not had sexual 
intercourse for several years (e.g., 5 years, 8 years).  This finding was also 
observed among long-term IDUs who did not have steady partners.   However, 
many respondents also were taking antidepressants, some types of which can 
affect libido.  We observed that Methadone and Subutex maintenance allowed 
for a return of sexual activity among some respondents, although some males 
reported experiencing a stronger sex drive with Subutex compared to 
Methadone.        
 
Some respondents had partners who had never injected.  In particular a number 
of young male respondents had female partners who had little experience with 
 Drug Use and Risk Behaviours among Injecting Drug Users 42
any drugs, except for weekend use of alcohol, and less frequently, cannabis.  A 
few of the female non-using partners had no knowledge of the male partner’s  
injecting drug use: 
 
Interviewer: “And what about your arms.  Does she ever ask what 
happened to your arms?” 
 
 Respondent: “She’s asked me.  I just say I was beaten up.” 
 
 Interviewer: “What about protection [condom use]?” 
 
Respondent:  “No that’s why I am worried for her.  The hospital told me I 
needed a test.”  (131)   
 
Among respondents who had engaged in sexual intercourse in the 30 days prior 
to the interview, very few had used a condom.  Moreover, when we asked the 
question about condom use, several respondents tended to assume that we 
were asking about birth control rather than about sexual risk for infectious 
disease.  A male respondent maintained with Subutex noted a return to sexual 
activity with his non-IDU female partner.  He and his partner confirmed that they 
had engaged in sexual intercourse approximately 12 to 15 times during the past 
30 days: 
 
 Interviewer: “What about condoms?  Would you use condoms?” 
 
 Respondent: “No, she’s got the f***y stopper [coil].”  (011)     
 
A male reported having a “one night stand” with a female: 
 
 Interviewer:  “So did you use a condom?” 
 
 Respondent: “No, she said she was on the pill.”  (111) 
 
Physical and Mental Health  
 
We asked people about their physical and emotional health.  The responses to 
this question appeared to be influenced in part by the timing of the last injection.  
Respondents who had injected a few hours before the interview often reported 
good physical health and some acknowledged that the timeliness of their last 
injection affected their self-reported health.       
 
Some respondents reported being in good physical health.  Others complained of 
ailments relating to injecting, e.g., venous damage, making injection into these 
sites either impossible or improbable.  Several males and some females reported 
injecting into the groin because of venous damage elsewhere.  Friends would 
often mark the vein with a pen and respondents generally were aware of the 
proximity to the femoral artery.  Sometimes the groin area was chosen to prevent 
non-IDUs from noticing the visible signs of injection.  Respondents noted their 
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embarrassment over damage to veins, particularly those located on the arms, 
wrists or hands.  Many sought to conceal the damaged areas by wearing long-
sleeve shirts, even in warm weather.  Getting clean or reducing the number of 
injections at times meant that respondents no longer needed to conceal the 
visible signs of injection: 
 
“Look at me. A nice day and I’m wearing this shirt [short-sleeve shirt].”  
(028)     
 
Other respondents reported problems with abscesses, septicaemia, irritable 
bowels, arthritis, osteoporosis, heart problems and lung infections/problems 
associated with smoking heroin and crack cocaine.  Some women, including 
those in their 20s, reported that they had stopped menstruating.  Many 
respondents reported having a poor appetite and some claimed that Subutex 
contributed to this condition.  Some had been prescribed a health drink that 
provided valuable vitamins and nutrients and increased the appetite.  A few 
reported that they had requested the health drink from their GPs but with little 
success. A 32-year old male reported that he had lost a large amount of weight 
but was denied a prescription for the health drink: 
 
 “He says it’s 24 quid a week and he won’t give it to me.”  (032) 
 
A male from another health board area reported a similar interaction with his GP: 
 
“I told him everything.  Just laid my cards on the table.  Lost three stone 
over the years and asked him for [health drink].  He said it was too dear.”  
(033)   
 
Some individuals suffered from panic attacks, and several had prescriptions for 
anti-depressants.  Indeed, self-reported depression appeared to be quite high 
among respondents.  A male reported being depressed before he ever used 
heroin and was depressed the day of the interview (while on Subutex):   
 
“I overdosed myself in the last three months.  One hundred diazepam and 
sleepers.  The break up [with the former girlfriend].  They cut me off them 
[anti-depressants] because I tried to overdose myself.  I’m alright now 
because it’s the daytime now.  But see at night, the depression…”  (137)      
 
Others reported being depressed during periods of abstinence.  Major withdrawal 
symptoms had long disappeared, however, to some extent cravings continued.  
Equally important, some respondents questioned their purpose for living and 
were bored with their current lifestyle.      
 
 
HIV, Hepatitis C and Hepatitis B  
 
We purposely chose to avoid asking respondents about any test results for HIV, 
hepatitis B and C because we did not have the expertise needed to address 
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post-test counselling issues.  However, we did ask people whether they had 
been tested and the number of times that they had been tested.  Additionally and 
without being asked, some respondents told us that they were positive for 
hepatitis antibodies.  Of the 53 people who were certain that they had undergone 
a test for hepatitis C antibodies, 30% reported to us that were positive (none 
resided in the Western Board).  In comparison, the Unlinked Anonymous 
Prevalence Monitoring Programme found that 16% of those participating in the 
2002 study had antibodies for hepatitis C.  The difference could be due to the 
different methodologies used in the two studies, the year of data collection, or the 
fact that the prior study was limited to respondents presenting at selected drug 
services in Northern Ireland.  In the present study, a total of 38% of respondents 
who reported being positive for hepatitis C antibodies were not in contact with 
drug services at the time of the interview.     
 
Respondents had thought a good deal about the source of transmission.  One 
male reported that he contracted the virus while in prison (not in Northern 
Ireland) because he tested negative for hepatitis C antibodies shortly before he 
was incarcerated.  Another male reported that: 
 
“I can tell you exactly when I got it.  I went over to a friend’s house.  He 
had a bit made up in spike.  I took it out of the spike and put it into a new 
one.  Took the needle off, drew the plunger out and poured it into a 
spoon…He’d sucked his bit out [before].  That’s how I got it like.  I was 
sick as a dog.  Pushing 48 hours.  Just not thinking…that one time, that’s 
all it takes.”           
 
We believe that the self-reported hepatitis C figure of 30% is likely to be an 
underestimate.  First, many individuals reported being tested one time only and 
did not appear to acknowledge or understand the need for regular testing.  
Second, some respondents had not been tested in several years.  For example, 
a female who had been involved in sex work noted her desire to be tested 
because her last test was conducted approximately three years before the 
interview.  Third, some were unaware whether testing had actually occurred, and 
at times there was confusion between hepatitis C and B.  For example, some 
respondents reported being immunised against Hepatitis C.  A female reported: 
 
“I was tested for hepatitis B.  No maybe it was C.  I don’t think I was tested 
for HIV.  But they take the blood because I’m pregnant.  Wouldn’t HIV 
show up in those tests?” (023)  
 
Fourth, 13% of the sample reported that they never had been tested for hepatitis 
C.  A female reported: 
 
“He’s been tested.  I don’t go for tests.  I just go by XXX’s [male partner] 
test.  He’s been tested for Hep C and all, and he’s clear for all that.  We 
haven’t shared with anybody [except between themselves], so I just think, 
if he’s clean, I’m clean, but I don’t know that [for certain].”   
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Interviewer: “And why would you not go [for testing]?” 
 
Respondent: “Why would I walk in and say, ‘I want a hepatitis C test’?  
Roll up my sleeve, they’d look at my arm.  If I didn’t have a daughter…”   
 
A few reported that they had not been tested because health professionals had 
told them that testing via blood was not feasible because their veins were so 
damaged.      
 
A few respondents actively pursued information about hepatitis C in particular:  
 
“People don’t want to know about Hep C.  They forget about sex.  They 
think it’s through the needle only.  It’s not.  They need to think about the 
spoon, sex, other things.  And the cold sores through smoking crack, and 
burns on the lips and mouth, that’s another way.”  (age 21) 
 
A male respondent had learned that he had the virus a year before the interview 
was conducted.  He was trying to stay clean and reported that his current social 
network included friends who had never used heroin.  They did not know of his 
status.  He tried to avoid alcohol because of the hepatitis: 
 
“I tend to get sick after a few pints.  I think they wonder if I don’t drink.  I’ll 
just get me a bottle of vodka and make very weak drinks.”     
 
The anticipation of telling other people was raised by other respondents.  A male 
reported:   
 
“I haven’t had a relationship in five years.  I’m getting clean now and I’d 
like one.  But how do you tell someone about the Hep C”?     
 
A respondent recalled feeling anguished about telling their partner but did so 
soon after diagnosis.  Members of the partner’s family had told several other 
people in the community: 
 
“Everybody found out.  And [they said that] I didn’t have Hep C, I had 
AIDS.  I had cups smashed behind me in cafés…”     
 
One male respondent had not yet disclosed to his female partner that he had 
hepatitis C.  Two respondents were partners who had been diagnosed with 
hepatitis C.  The interviewer asked whether they knew about interferon treatment 
to which the female respondent replied: 
 
“It’s terrible.  You lose your hair, you get sick, withdrawal, stomach aches.  
You need to get six injections a day.  We’re not interested.” 
 
Respondents voiced frustration about the apparent ten-day wait to obtain results 
from their test for hepatitis C antibodies: 
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“In Europe it’s the same day. It’s frustrating.” (001)   
 
At the time of the interview, a female had been waiting for three years to obtain a 
referral to see a liver specialist.  The consultant psychiatrist had recommended it, 
but the GP was slow to make the referral.  A male respondent reported that he 
was “expecting” to be told that he had hepatitis C Virus because “I shared with 
people – needles, filters.”  He also voiced frustration in the wait for diagnostic 
tests: 
 
“Now I’m waiting for the test results to find out what strain it is.  You see it 
takes at least six weeks to get those results back.  There are different 
strains of Hep C – six different strains I think.  Some are treatable and 
some are not.”   
 
We asked respondents to provide an estimate of the number of other current 
injectors whom they knew.  These “other injectors” included partners, friends, 
relatives and acquaintances.  Thirty-nine percent of respondents knew in access 
of 100 other injectors, particularly those respondents residing in the Northern 
Board.  We did observe substantial regional differences when we asked about 
the number of injectors whom they knew who had hepatitis C or HIV infection.  
Despite knowing several injectors (often in excess of 100 other IDUs), Northern 
Board respondents knew very few injectors with hepatitis C.  This pattern differed 
greatly from what we observed among respondents residing in the Eastern Board 
who tended to report that half, most, or every IDU they knew had hepatitis C.     
 
Overall we found that respondents had considerably less knowledge about 
hepatitis B than they did about hepatitis C or HIV: 
 
“People wouldn’t mention that they have Hep B.  That’s for people who are 
sleeping on the streets, people who are alcoholics, people who work in 
hospitals” (113). 
 
No one reported to us that they had antibodies to hepatitis B core antigen and 
only 17 respondents reported that they had been fully immunised against 
hepatitis B.    
 
None of the respondents told us that were HIV-antibody positive.  Approximately 
15% of respondents had never been tested for HIV antibodies and 6% did not 
know whether they had been tested.  A number of respondents had been tested 
one time only.  Additionally, 63% of respondents did not know any other injector 
with HIV.     
 
 
Experience with Drug Services 
 
The interview data revealed three broad groups of IDUs: 1) respondents who 
were in contact with drug services (statutory or voluntary) at the time of the 
interview (40%), 2) respondents with a history of engaging or attempting to 
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engage in drug treatment but who were not in contact with services at the time of 
the interview (43%), and 3) respondents who had never been in contact with drug 
treatment services (17%).  We found considerable differences across board 
areas.  A total of 62% of respondents from the Northern Board were in contact 
with treatment services at the time of the interview, compared to 23% of 
respondents from the Eastern Board.  Four of seven respondents from the 
Western Board were in contact with drug services in Northern Ireland.  None of 
the five respondents from the Southern Board were in contact with drug services 
at the time of the interview although all expressed an interest in treatment.  A 
large number of respondents from the Eastern Board (65%) had previous contact 
with treatment services, compared to 19% of respondents from the Northern 
Board.        
 
It is important to note that this study was not an evaluation of drug treatment 
services.  Such an approach would need to be carefully designed and would 
require the use of one or more control groups.  A thorough evaluation would 
benefit from multiple interviews with clients over a lengthy period of time and 
treatment providers would also need to be interviewed.  With these caveats in 
mind, we report the findings here to indicate respondents’ perceptions and 
experiences with drug services.    
 
We observed that a number of respondents who had been in contact with drug 
services, particularly in recent years, reported positive experiences and good 
relations with staff.  Drug services appeared to provide a range of services for 
some respondents.  One young male respondent had injected for the first time 
seven months before the interview.  He was a member of a small network of very 
young IDUs from Belfast, all of whom had initiated injection during the same time 
period.  His drug use (injecting diazepam, DFs and morphine about four times 
per day during the past 30 days) and severe depression led him to contact a 
statutory drug agency one week before the interview.  Staff there provided him 
with information about infectious disease and told him about the needle 
exchange.  He reported being surprised after learning about the relationship 
between injecting behaviours and hepatitis C.  He had injected about 120 times 
per month for the past seven months before learning how to access new and free 
needles and other injecting equipment.  He began to utilise the needle exchange 
about a week before the interview.  Prior to that time, he and his mates would 
use the same needle several times, “You should have seen the arms.  All cut and 
all" (131).  Clearly, the drug service had assisted him greatly in terms of reducing 
the harm associated with drug injection.   
 
A number of respondents reported that staff in community addictions and drug 
outreach were instrumental in helping them locate and access a GP or assisting 
them in other ways: 
 
“I first went to the GP – had to, I was dying.  I asked for DHCs.  He bucked 
over.  Pathetic.  Gave me diarrhoea tablets.  Went to Community 
Addiction and they got me a GP.  Came up with me, helped me get on 
something [i.e., substitute prescribing].”  (011, male)    
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Respondent:“I shared with XXX and XXX and they’ve got Hep C.  I told my 
key worker and he took me to the GUM clinic.  All clear.”  
 
 Interviewer: “Your key worker drove you there?” 
 
Respondent: “Yeah, drove me there, waited and drove me back.  They do 
that for you.  Brilliant so they are.”  (025) 
 
We observed important differences across health board areas with considerably 
more favourable reports in one health board area in particular.  In one other 
health board, we failed to observe any positive feedback at all.  Some 
respondents who were dissatisfied with drug services in their area sought 
treatment in another health board.  Some had made attempts to utilise a friend or 
relation’s home address in order to obtain services in a health board other than 
their own.   
      
Of those respondents who had never been in contact with drug services, some 
believed that contact would affect their employment or future employment.  A 
male reported that his GP recently gave him a referral to a statutory drug service.  
He had not yet attended at the time of the interview: 
 
“I don’t want to be a registered addict.  It’s already affected my life – 
personally, physically, mentally.  And I don’t need it in writing.  I don’t need 
that label attached to me.  Kind of like sex offenders, you’re on some sort 
of a list and you don’t know who is looking at it.”  
 
Others reported that they could not access drug services because their family 
members believed them to be “clean.” We also observed gender differences with 
regards to participation in treatment services.  That is, 44% of males were in 
contact with drug services at the time of the interview, compared with 30% of 
females.  Female respondents voiced concerns over the placement of their 
children if they were to be identified as a drug user: 
 
“I remember when she [social worker] first came in here.  She said, ‘How 
can you be a heroin addict when your house is so tidy?’  We call them 
book readers – think they know everything about heroin use.  All these 
myths they believe them.  Like why can’t a heroin user keep a tidy house?  
My child – I bathed him every night, he was always fed, and always had 
his nappy changed.  Well looked after.  Well cared for.  But see when you 
get these? [Points to a small box of DFs], you’re marked.  That’s what gets 
them [Social Services] involved at first.  I know a girl, two kids and they 
are always begging for sweets in front of the shop.  Wee things, have dirt 
between their fingers.  But she’s never lost those kids.  Buys her DFs from 
the street, no script at all.  So no one knows about her.”  (034)   
 
We interviewed another female who had never been in contact with drug 
services.  Nor did her GP know about her heroin use: 
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 Interviewer: “So what’s stopping you from going [for treatment]?” 
 
Respondent:  “Social Services.  My main worry is my daughter…I am just 
so paranoid about XXX [daughter].”  (112)   
 
Respondents residing in rural areas or small villages located a good distance 
from large towns had reported frustration at the lack of facilities in their areas.  
Some respondents had made several attempts to access drug services in 
various health board areas: 
 
“I went into the clinic that night [this clinic was NOT part of addiction 
services nor was it another drug service].  That was the sixth time I had 
tried to get help.  The sixth time.  One time my Probation Officer tried to 
get me into that place in Belfast – XXX [voluntary agency that focuses on 
drug and alcohol].  We found out I had to come up with £400, [or 
alternatively] I had to move to Belfast.  I [was required] to pay but just 
didn’t have the money.  My [former] boyfriend and I heard about [Addiction 
Unit located outside their health board area).  We went to three or four 
doctors there trying to get into the place.  None of them could help us.  
That night in the clinic, I was so sick.  They didn’t give me anything. I got 
cheeky and they put me in lock-up.  Why didn’t they send me to the XXX 
[local addiction services]? Why didn’t they tell me about it?  I was there for 
a bit, and then this XXX [drug worker/counsellor] and XXX [consultant 
psychiatrist] came to see ME in the clinic.  They told me about Subutex.”   
 
In this instance, there were six occasions where she tried to get help for heroin 
dependence.  She attempted to access services in two other board areas – 
neither of which was her own.  She was not successful because of the “residency 
requirement.”   
 
 
• History of negative experiences  
 
A number of respondents had attempted to engage with drug services on at least 
one occasion, and several reported multiple attempts. Often this treatment 
history shaped their perceptions of current treatment practices.  Extremely 
negative experiences with drug services contributed to total avoidance of all 
treatment services.  Britlofex in particular was described as a “primitive” drug.  A 
34-year old male recalled his experience with a drug service in the year 2000: 
 
“He [Consultant Psychiatrist] told me he could cure my heroin addiction in 
five days with Britlofex.  I said, ‘With what?  Britlofex?’ I had to laugh.  I’d 
been on meth for over 10 years and knew it worked for me. And here’s 
this man so concerned about his job and he thinks he can cure me.  I got 
cheeky with him.  He told me if I came back he’d call the cops.”  (015) 
 
A male went through detox at a statutory drug service and was given Britlofex. 
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“I told them I couldn’t sleep, I was very stressed.  I told them that I’d need 
Valium prescribed with the Britlofex. They said to go to my doctor to get 
those things because they couldn’t prescribe them.  Then they phoned my 
doctor behind my back and told her not to give me any.  So then I made 
the appointment with the doctor and she showed me on the computer 
screen.  XXX [statutory agency] phoned her and told her not to prescribe 
diazepam under any circumstances.  So they told me to go to the doctor, 
and then went behind my back.  I was sick at the time and I didn’t need to 
be getting out of my bed to go to the doctor.  If they had of told me the 
truth instead of lying to me – that’s what they did – they lied to me.  So 
how are you supposed to trust a place like that?  I’m still angry about it.  I 
told the doctor about it.  I said, ‘There’s no way I’m going near this place.’ 
…Five days later – five days of Britlofex and I was crawling the walls, 
hadn’t slept in five days, I was sick, and I relapsed…We should be offered 
the same level of service as the rest of the UK.”  (103)  
 
A male respondent reported undergoing in-patient detoxification on two different 
occasions.  He was detoxed with Britlofex and relapsed within five days after 
completing the detox.   Another male respondent provided similar reports about 
the same drug service and relapsed shortly after he completed the detox 
programme: 
 
“Dr XXX [Consultant Psychiatrist] is not a nice man.  No help at all.  Gave 
me Britlofex.  He told me, ‘I’m not going to give you methadone.  And you 
don’t need sleeping tablets.  You’ll sleep OK here.’ I never slept at all the 
whole time I was there.  There were mostly people in for alcohol and they 
slept fine.  I’d hear them snoring at night and I was crazed.  I wanted to 
sleep so badly.” (018) 
 
In all four board areas, information about treatment practices passed quickly 
through social networks of injectors.  One person’s negative experience with a 
particular drug service contributed to the avoidance of treatment among other 
IDUs.     
 
 
Concerns about dispensing 
  
Some respondents reported that they had developed very good relationships with 
chemists from whom they collected their prescriptions.   
 
“My chemist has changed.  The [former] pharmacist was discreet.  Called 
you into the back and had a good chat with you while she was waiting for 
the Subutex to dissolve.  I’m going to ask Dr XXX can I change chemists.  
In this new one there’s no private part.  They just call you up to the front of 
the shop so it means everybody can see you.”  (143)   
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Similar to the experiences in the pharmacy-based needle exchanges, many 
respondents noted that the lack of privacy in pharmacies created anxiety for 
them when accessing substitute treatment: 
 
“Sometimes I have to wait half an hour to get my meth.  She has to serve 
everyone first, even people who come in after me.  I’m waiting there and 
people looking at me like I’ve got two heads.  She’s getting paid for 
helping us, but you feel like you have to kiss her toes.”  (025)   
 
Many respondents attempted to collect Subutex or Methadone in the morning 
because there were fewer customers present.  Additionally, some individuals 
needed a morning dose to prevent sickness.  Other respondents noted that early 
morning visits often meant that they would not come into contact with other IDUs 
– visible reminders of their previous lifestyles or perceived sources of temptation.    
 
Respondents who continued to inject or subsequently injected while being 
maintained with Methadone or Subutex, voiced concern about being removed 
from a programme of substitute prescription because of a positive urine test for 
illicit drugs.   
 
“He [staff member in drug service] was going to throw me out.  I begged 
him.  I wouldn’t leave the building.  I was in tears.  He finally said, ‘Alright.’”  
(013) 
 
In particular, respondents who resided in small towns were concerned about 
confidentiality in local pharmacies:   
 
“I would be nervous going in there.  There’s a few reasons.  Your ordinary 
people come in and get their prescriptions.  Could be your mom’s mate, 
someone down the lane, someone in the UDA.” (144) 
 
A male reported a number of problems with the local chemist from whom he 
collected his substitute prescription.   
 
“There’s one chemist in the village and everybody knows me.  Everyday I 
go in there and they see the man put the tablet on the spoon.  You have to 
sit there, waiting for it to dissolve.  There’s no privacy.  So much for the 
confidentiality of the chemist.” 
 
Respondents questioned the reasoning of daily collections: 
 
“The doctor knows that I need it.  I’m not going to eat it all at once.  That’s 
stupid, you’d just be sick.  I need my daily drugs.  That stabilises me.” 
(104)  
 
He reported that a person who works in the chemist knew people that he did.    
Such is the nature of villages.  However, the respondent believed that the staff 
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person in the pharmacy had told others about the respondent’s involvement in 




“My work has stopped.  A friend asked me, ‘Why do you go to the chemist 
each day and take that tablet?’  Who told him about the Subutex?  [We’ve] 
no dirty urines…I’ve told Dr XXX [Consultant Psychiatrist], ‘Test us, 
surprise us [with a urinalysis test]’ we just can’t be going in there every 
day.’ The first couple of weeks were terrible.  She [staff member in 
pharmacy] stood over me.  I wiped my eye and she reported it to him 
[head chemist].  No trust at all.”  (020)   
 
We learned that a chemist in one small village had only a few clients on 
maintenance.  The chemist knew that the clients were acquaintances:   
 
“She’s asking me how XXX [other client] is doing and she asks him how 
I’m doing.  She’s not supposed to ask that, is she?  Pure nosiness.  She’s 




• Lack of involvement in treatment decisions  
 
Respondents who reported having little influence over treatment decisions often 
left treatment and relapsed.  Some respondents recalled a “one size fits all” 
approach to drug treatment and found that approach to be unsatisfactory.  For 
example, a male injector made three attempts to seek help (a statutory agency, a 
voluntary agency, and a psychiatric ward).  In all three sites he was forced to 
engage in counselling: 
 
“They say more counselling.  I don’t need counselling.  It’s the same old 
questions about my background and relationships.  I don’t have any family 
trauma, no addiction, no nothing...I wasn’t bullied, there was no child 
abuse.  I keep telling them this but the same old questions they ask.  Why 
do I need counselling?  It does no good for me.  I get my hopes up every 
time I have an appointment.  I think, ‘Maybe this time [they can help me].’  
But nothing.  Then I come home more depressed than when I went in [to 
the drug service].  You get really down because you keep making these 
appointments with these so-called professionals and they know F*** all 
about my addiction.  Don’t get me wrong, the counsellors I’ve had are nice 
people.  But I need more than nice…There’s no help here for people.  The 






 Drug Use and Risk Behaviours among Injecting Drug Users 53
• Dissatisfaction with detox only 
 
A number of respondents indicated that they needed more intervention after 
completing detox.  A male had been in the same in-patient detox centre on five 
different occasions.  At one point he was in three times in one year:   
 
Respondent:” The girls at XXX [statutory agency] are dead on.  They 
really want to help.  But they don’t have enough information or experience 
to deal with heroin addicts.  They start you on a low dosage of Subutex, 
raise you and then reduce you.  Then they release you.  And it’s then that 
you start withdrawal.”   
 
 Interviewer: “How long were you in for?” 
 
Respondent: “14 days.  That’s another thing, I think that 14 days is far too 
quick.   I think six weeks or so is more realistic.”   
 
Interviewer: “All those five times that you were in, did you ever stay clean 
after you left?” 
 




Respondent:” Absolutely useless.  No concept of drug users at all.  I think 
they are used to dealing with alcoholics.  The shock therapy might work 
for alcoholics but it certainly doesn’t work for heroin addicts.”  
 
Interviewer : “What do you mean by shock therapy?” 
 
Respondent: “Go clean that’s it.  Stay for two weeks, back on the streets, 
not going to use again.  People have habits for 10, 15 years.  How can 
they ever stop just by that detox?  Because they can do that [detox] at 
home.  They can get better drugs off the street to detox yourself.  Kind of 
pointless really.  Kind of a fundamentalist Christian attitude underlying 
it…They don’t abide by clinical guidelines.  I know they are just guidelines 
but…Do you know about the clinical guidelines that were published in 
1999?  About substitution therapy for opiate addicts?  Basically loads of 
doctors drew up a plan for the NHS of how to deal with heroin addicts. 
One of the key things was that someone with a long-term problem should 
be offered maintenance therapy.  No pressure to come off it, only when 
you’re ready.”  
 
Interviewer: “Is this applicable to Northern Ireland?” 
 
Respondent: “That’s the strange thing.  [Officially, it’s known as the] 
United Kingdom of Great Britain and Northern Ireland!”  (105, interviewed 
before April 2004) 
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A 25-year old male described the time that he went through detox at a drug 
treatment facility: 
 
“You’re allowed one visitor so your friends can’t come visit.  You need a 
separate room to come off the gear [but none is available there].  [When 
detox is completed] you walk out the door onto XXX [local area where 
drug transactions occur frequently].  No one ever managed to stop using.”  
(001) 
 
A 27-year old female had engaged in detox with drug services on four different 
occasions.  She offered a similar description and noted the monotony of the 
service: 
 
“There’s nothing to do.  They should keep you busy with meetings and 
activity.  There is no rehab – just detox.  You are on your own, few people 
to talk to.  You get out and that’s it – XXX [same local area where drug 





A total of 38 respondents (42%) were on Methadone or Subutex maintenance at 
the time of the interview.  Subutex dosage ranged from 4 to 14, with most clients 
receiving a dosage of 8 or 12.  Dose levels for Methadone ranged from 35 to 85, 
with 65 mg being the most common dosage.  These individuals were pleased 
that substitute prescribing was now in place.  A male on Methadone maintenance 
reported: 
 
“I’ve got no problem with Dr XXX [Consultant Psychiatrist] now.  At first I 
thought he was using the wrong methods.  The wrong sort of methods for 
heroin addiction.  I mean [years ago] I was prescribed Thorazine for 
addiction.  That’s an anti-psychotic drug.  They just didn’t know.”  (028)  
 
In general, we observed that respondents receiving Methadone or Subutex 
maintenance reported positive benefits of the interventions.  For example, some 
respondents had fairly long periods of abstinence from heroin or other opiates 
since commencing a maintenance programme.  All of the 38 respondents on 
maintenance had reduced the frequency of injection.  Several, for example, 
recalled that they had previously been injecting daily or several times daily 
whereas at the time of the interview were injecting a few times per month.   
 
In some health board areas, we observed an apparent preference among some 
drug service staff for either Methadone or Subutex.  Indeed one staff member 
told a respondent that Subutex was the “preferred substitute drug of choice” in 
that health board area.  A preference for one substitute drug over another 
(indeed a blanket policy appeared to operating in some areas) was justified in 
terms of “clinical judgment,” which often failed to consider individual needs.  For 
example, one male respondent who did not meet the study criterion of injecting in 
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the past 30 days, had been on Methadone maintenance in another jurisdiction for 
a period of several years.  With clinical support in that jurisdiction, he had 
reduced his dosage to 65 mg per day.  He reported that the intervention had 
worked well for him for several years and that he was pleased with his progress.  
Upon presenting for treatment in Northern Ireland, he was offered Subutex only 
with a two-week stay in an addiction unit while he detoxed from Methadone.  He 
faced the dilemma of continuing to travel twice weekly to collect his prescription 
in another jurisdiction, or switching to Subutex. He had stabilised well for several 
years without any problems with Methadone.  Why then would “clinical judgment” 
seek to change that?  To us, it represented a risk for relapse and also presented 
ethical issues in terms of clients’ input into treatment decisions.           
 
We interviewed four respondents who had switched from Methadone to Subutex 
and six individuals who had switched from Subutex to Methadone.  A 33-year old 
male had been switched on four separate occasions for a total of five separate 
treatment episodes in two different locations, involving either Methadone or 
Subutex.  Very little research has examined which substitute drug works best for 
particular individuals so that clinicians often lack guidance regarding the 
appropriate choice of substitute drug.     
We did observe that some respondents on Subutex maintenance began to 
experience cravings in the early hours of the evening.  A male respondent was 
on 10 mg of Subutex for three to four months but reported:   
 
“It didn’t work for me.  It did the job until 4 or 5 in the afternoon, then I got 
cravings real bad.” (021)   
 
For some people, cravings and withdrawal appeared to be related to setting.  For 
example, a female reported feeling no effects of withdrawal after being stabilised 
in an addiction unit.  When she returned home, however, the withdrawal effects 
began to surface.  She purposely avoided collecting her Subutex until late 
afternoon in hopes of preventing the effects of withdrawal at night.     
 
One respondent had been on 8 mg of Subutex for approximately one year but 
reported that the dosage did not “hold” him.  At the time of the interview he had 
been on Methadone for one year and had reduced his injection frequency from a 
number of times per day to once a month or less: 
 
“Sometimes I’d go a month without using.  Then I’d have a dig and feel 
bad.  I’d wonder why I did it because with the methadone, you don’t get 
much effect [from heroin].  Waste of money.”  (028)    
 
Other respondents on substitute prescribing preferred Subutex to Methadone 
and some were adamantly opposed to Methadone: 
 
Respondent: “I wouldn’t touch it.  Offered it, but it absorbs into the marrow 
in your bones and it takes months, years to get out of your system.”   
 
 Interviewer: “Who has told you this?” 
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 Respondent: “A doctor.” 
 
 Interviewer: “Your GP?” 
 
Respondent: “No, a doctor who was standing in for Dr XXX [Consultant 
Psychiatrist].”  (137) 
 
 
• Daily collections of Subutex or Methadone. 
 
Daily visits to a pharmacy created problems for some respondents, particularly if 
they were seeking to find employment: 
 
“I need to get a job.  But I go to the chemist everyday [for Subutex].  What 
if the job’s in Antrim?  How am I going to get my Subutex?” (011)  
 
A 31-year old male reported his interest in finding employment: 
 
“It’s too much hassle.  I got a phone call, says would I like to have the job.  
I was interested.  It started though at 8.00 in the morning and finished 
around 5.30.  How could I get the script?  I needed to be in town at 9.00 or 
9.30 or else be back by 4.30 or 5.00.  I need to find work that allows me to 
get my script.”  (028) 
 
Some respondents lived far from the dispensing chemist, even though other 
chemists were located closer to their residence.  One male travelled by bus six 
days a week to the pharmacy where he collected his prescription.  He left on the 
bus each morning at 7.30 and returned to the town of his residence at 1.30 pm, a 
journey of about five hours each day.  The return bus fare cost him five pound 
sterling each day, reduced because of his DLA eligibility.  He reported that the 
drug service was actively trying to find a chemist located closer to his residence, 
and who was willing to dispense.      
 
 
• Lifestyle changes 
 
Substitute prescribing contributed to major lifestyle changes for a number of 
respondents.  They were able to form new friendships with people who had never 
injected, or re-establish links with former friends who had never injected.  One 
planned to go to a concert with new friends:   
 
“I never would have done that if I was on the gear.  Just didn’t want to go 
anywhere or be with anybody.”  (028) 
 
These new or “rekindled” social networks at times focused on alcohol use, 
a substance that was generally avoided when people were using heroin.  
A 28-year old male had been on Subutex maintenance for several months.  
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He reported that he was drinking four to five pints per night, several times 
a week largely because we interviewed him during football season.  His 
lifestyle had changed tremendously since he started a Subutex 
programme.  At the time of the interview, he was spending time with his 
former mates who had never injected.  He noted that alcohol was 
consumed often within this social network.  Regardless, he described how 
Subutex has allowed him to be trusted again by his friends: 
 
“Now I’m running about with my mates, my old friends.  That’s helped.  I 
remember sitting there in the pub and XXX [male friend] ran out of money 
and gave me his card and pin number [to obtain money from the cash 
machine].  That’s the best thing – gaining back their trust.  I was skipping 





The overlap of social networks of injectors creates a setting whereby information 
about treatment and changes in treatment policy travels quickly, unless 
individuals are unconnected to one or more networks of injectors.  Several IDUs 
knew of respondents or had heard of respondents who were able to “bypass” the 
waiting list and receive quick entry to a detox programme.  Some believed that 
the perceived “system” was unfair.  In some health board areas, getting a place 
in detox was perceived to be the “luck of the draw.”  However, we observed that 
individuals who had experienced severe depression or who had attempted 
suicide, were able to circumvent a waiting list and be admitted quickly.  For 
example, a young male reported knowing several people who were waiting for a 
place in a detox setting.  He noted that his girlfriend had become extremely 
depressed from using heroin and was found to be “curled up in a ball on the 
Thursday.  She was in XXX [drug service] by Tuesday” (005).  A female 
respondent had smoked heroin for years and injected heroin for the first time a 
week before she was interviewed.  Two weeks later her friend had phoned the 
interviewer and stated that the female was “in a bad way.”  The respondent was 
extremely depressed and reported being desperate for a place in the local detox 
facility.  She had been given an appointment for the following week but told the 
researcher, “I don’t know if I’ll be here [alive] then.”  She was suicidal and her GP 
had told her to ring a crisis response team if she had difficulties over the 
weekend.  The interviewer made contact with the female at several points over 
the weekend; the GP never visited the house nor did he follow-up with a 
telephone call.   The drug service, however, found a place for her in the local 
addiction unit a few days later.  Some males also reported an immediate entry 
into an addiction unit after they had attempted suicide.  Clearly these events 
prompt immediate access to drug treatment.  We were surprised, however, at the 
lengthy wait to obtain access to services for other respondents.  
 
The waiting list created problems for people because the desire for treatment can 
vacillate over brief periods of time.  A female who had never been in treatment 
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reported that she was on the waiting list for placement in an addiction unit.  Her 
male friend had already been through the programme: 
 
Interviewer: “I heard there’s a wait to get in there.” 
 
Respondent: “Yeah, sometimes six months.  When addicts want treatment 
they want it now.  They’re ready now.  They may not be ready in six 
months.” 
 
Interviewer: “So do they contact you and tell you when to come in?  Do 
they give you some notice?” 
 
Respondent: “They say, ‘Come tomorrow, or come the next day.’  You 
have to be ready to go.”  (032) 
 
 
Outreach Services  
 
Shortly after the interviews commenced, we observed that several respondents 
most of whom resided in areas outside of Belfast, raised questions or issues with 
us that often called for expertise from other professionals.  For example, we were 
asked about treatment options, ways to access treatment, pregnancy and 
treatment, conditions of treatment, benzodiazepine withdrawal, housing, access 
to children, locations of needle exchange, and a host of other things.  On most 
occasions we made contact with relevant experts after the interview concluded 
and then followed-up with respondents.  At times we found ourselves in an 
advocacy role and we know that this role might have created pressure for some 
staff in drug services.  Nevertheless, the expansion of our research role is indeed 
a “finding” of the study.  That is, injectors were searching for information or 
support that for one reason or another was not accessible to them.  This finding 
indicates a gap in services in that most if not all of these issues could be 
addressed through drug outreach.             
 
Respondents in Belfast who had been in contact with drug outreach services 
reported very positive feedback.  Outreach served as a gateway into treatment 
and provided other services as well.  For example, some GPs refused to treat 
respondents once they disclosed their drug use.  Outreach assisted in obtaining 
a new GP, a crucial link to health care and treatment.  Additionally, respondents 
noted:   
 
“That outreach team.  Really sound.  They helped me get on the Meth and 
I haven’t been clean this long in years.  And they help with these forms as 
well.” (030)  
 
“Outreach – brilliant so they are.  Real respect for XXX [outreach worker].  
They phoned me at the hostel, said, ‘I’ll be there in half an hour.’  Couldn’t 
believe it.  In XXX [city in England] it’d be six months.  Phoned my mum, 
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told her.  I said, ‘Can you believe they were there in a half an hour?’ “ 
(033)   
 
Regardless of whether Belfast respondents had been referred to the study by the 
Drug Outreach Team or by some other source, we failed to observe any negative 
feedback regarding drug outreach services in Belfast.    
 
 
Self-detox and Other Methods to Get Clean 
 
Some respondents had utilised various methods for self-detoxification, without 
the intervention of drug services.  These periods of detox were described as 
being very difficult and people sought different means of motivation.  A 25-year 
old male recalled his most recent detox episode: 
 
“A friend of mine was going on holiday and there was a month left on the 
flat.  He told me I could stay there.  I had hit rock bottom.  I locked myself 
in for a week – no food, no Valium.  I turkey’d it out.  A friend brought me 
hash and I slept for a half hour…I was reading two books: Junkie by 
William Burroughs was one.  I don’t know what your politics are but I read 
about Bobby Sands.  I figured if he could have that much discipline, 
starving himself for what he believed, going without food for so long, I 
could go without gear.  That was real motivation for me.” (001)   
 
After arriving from England, a male respondent attended drug services in 
Northern Ireland where he declined Methadone and Subutex: 
 
“I don’t want a prescription drug.  Meth is worse to come off than gear.  
Takes twice as long.  And people are injecting the Subutex.  I did it 
[detoxed] myself before.  [This time] I was getting on the plane – had 200 
pounds in my pocket and nearly didn’t get on.  Thought I would go for a 
bag.  But I’m here.  Getting easier each day.  You know that, ‘one day at a 
time’?  That’s what I say every morning.  Just want my life back.  Used to 
have everything – mortgage, beautiful woman, car.  Then found myself 
sleeping in a bin shelter.  Blood everywhere from trying to find a vein.  
Thought, ‘How’d I get here?’ “ (033) 
 
Most of the individuals who had moved away from drug user networks and 
associated lifestyles eventually relapsed.  A 29-year old male recalled how he 
moved from his hometown to another town in which few users resided in order to 
“get away from the gear”: 
 
“But you always come across a group [of users].  I don’t know what it is.  
Either they find you or you find them.”  (019) 
 
Getting clean was perceived as easier than staying clean.  A male reported the 
difficulties of abstaining from heroin for one year: 
 
 Drug Use and Risk Behaviours among Injecting Drug Users 60
“All I could dream about was heroin.  It’s crazy.  I don’t want to be on 
heroin but I’ve been on it so long my mind is fixated on it.”   (104) 
 
 
Relationships with General Practitioners and other Health Professionals 
 
Nearly all respondents reported having a GP at the time of the interview.  Some 
respondents had never disclosed their drug use to their GPs: 
  
“I was doing great.  And then he stopped the script.  He [male partner] was 
helping me because I wouldn’t go to a doctor.  I wouldn’t go to a doctor 
and say, ‘I’ve got a heroin habit.  I need help.’  So he was giving me half of 
his.  Whenever we had no diffs [Dihydrocodeine], we started the gear 
again.”  (112).   
 
Others reported that they were the first “addict” ever to be seen by their GP.  A 
number of respondents reported having excellent relationships with their current 
GPs.  However, several attempts had been made to find a doctor who 
understood drug dependence.  Respondents recalled their relationships with their 
former GPs: 
 
“He was clueless.  He said to me, ‘Why do you choose to take heroin?’  
He didn’t want any junkies.” (001) 
 
 
A male reported:   
 
“A GP [long-term family doctor] actually told me that it’s my problem and I 
should deal with it myself.  That’s my family GP so a friend recommended 
[another] GP.  Went and seen him.  I had to convince him that I was 
serious about staying off heroin.  I asked for Subutex, Valium.  He had to 
go to Dr XXX [Consultant Psychiatrist] and ask if he could prescribe 
Subutex.”  (104) 
 
A few homeless respondents reported the difficulty in getting a GP without a fixed 
address.  Others had given up hope:   
 
“I have been to seven or eight GPs but they’re all the same.  They can’t do 
anything for me.  I’m fed up chasing GPs.” (008) 
 
His previous GP had prescribed ten Dihydrocodeine, and reduced it each day: 
 
“Would you believe what my GP told me? She said that I might as well 
keep using [heroin] because she can’t help me anymore.”  (008) 
 
A 31-year old male reported that his former GP tried to remove him from her list 
of patients: 
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“It was right after Dr XXX [Consultant Psychiatrist] had told me that the 
GPs were going to give the scripts out.  Right after that, I got a letter from 
my doctor that she was striking me off.  I don’t know if it was a coincidence 
or not.  I rang for an appointment and couldn’t get one.  Said I wasn’t a 
patient after 30 days.  Went to my key worker and he contacted the GP.  
Then she said she would keep me but I had to sign a contract saying I 
would not use any more.  The thing was, I was going there as a heroin 
addict.  I never tried to hide that.  How could I sign a contract saying I 
wouldn’t use again?  Now I’ve got Dr XXX [a new GP].”  (028)     
 
Other respondents also reported being forced to sign contracts: 
 
“They make you sign a form and all.  Call it a contract or something.  Now 
there’s XXX [acquaintance], now he can be violent. But why do I have to 
sign it?  They just don’t trust junkies, even junkies who are trying to come 
off it.  (035) 
 
 “I get DHCs from my GP.  Made me sign a contract.” 
 
 Interviewer: “What kind of contract?” 
 
Respondent: “I had to say, ‘I’m a heroin addict’ and abide by the rules.” 
(037) 
 
Respondents described their experiences with other health professionals.  A 28-
year old male respondent recalled that he overdosed immediately after he 
injected heroin for the first time: 
 
“My mates took me to Antrim Hospital A and E.  That was 1995.  That 
doctor came over, looked at me and said, ‘Someone else can deal with 
him – I’ve no time for these boys.’  Times have changed, yeah?”  (024)   
 
Several respondents had not been to a dentist in years, despite having problems 
with their teeth.  A few used the School of Dentistry in the Royal Victoria Hospital.  
Some respondents who reported to us that they had hepatitis C noted problems 
when they disclosed this status to their dentist: 
 
“Family dentist – he’s been my dentist all my life.  As soon as I got the 
Hep C I told him and he told me that he wouldn’t treat me anymore.  Had 
to go to Dr XXX in the Royal.”  (110) 
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LIMITATIONS OF THE RESEARCH  
 
A potential problem can arise when researchers recruit IDUs from treatment 
settings.  That is, agencies can act as gatekeepers and selectively refer their 
“best” clients to participate in a study.  We also were interested in recruiting 
respondents who were not in contact with drug services.  For these reasons we 
did not “advertise” through drug treatment venues until six months after the 
interviews commenced.  In all, two statutory drug services referred clients to the 
study and staff within those agencies were most helpful (e.g., some made 
telephone contact with the researchers directly, while the client was in the 
venue).  In particular it was found that respondents residing in the Northern 
Board were more likely than other respondents to be in contact with drug 
services at the time of the interview.  We observed this pattern occurring both 
before and after April 2004, when substitute prescribing for maintenance 
purposes was implemented fully.  We began to ask respondents in the Northern 
Board if they knew other IDUs who were not in contact with drug services there.  
Although respondents reported knowing some individuals who were not in 
contact with drug services, most stated that the majority of the experienced 
injectors known to them had been in contact with drug services in the board area.  
We are unable to determine whether the finding was due to the perceived 
benefits of drug services in the Northern Board or whether it was due to a 
methodological artefact. 
 
A second limitation of the study is that it is based on cross-sectional data, i.e., 
data collected at one point in time.  In some of our follow-up conversations with 
selected respondents we observed that some had made contact with drug 
services since the interview, whereas others were using more frequently or had 
relapsed. We feel that drug use patterns and lifestyles can change rapidly among 
some IDUs and that cross-sectional data are limited in their ability to measure 
change.   
 
A third limitation concerns our inability to generalise to the wider population of 
injectors in Northern Ireland.  Drug use is a sensitive topic and drug users 
represent a hard-to-reach population.  For these reasons, random samples of 
IDUs are not possible, thus, it is not known whether the results of the study are 
generalisable to the wider population of IDUs in Northern Ireland.  However, 
qualitative data are best suited for sensitive topics with a hidden population.       
 
Finally, we often were unable to “count” the number of times that respondents 
had engaged in particular behaviours.  We observed that several quantitative 
measures of behaviours generated confusion and at times, frustration, during 
interviews.  We acknowledge, however, that persons who are in positions to 
influence drug policy often prefer quantitative data.          
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RECOMMENDATIONS   
 
Recommendation 1:  It is recommended that the DHSSPS develop 
additional ways to distribute information on all aspects of safer injecting to 
IDUs.   
 
The findings indicate that many IDUs lack knowledge with regards to the risks 
associated with loaning and borrowing injecting equipment, particularly 
equipment other than needles and syringes.  Although some respondents 
reported that they loaned and borrowed used equipment from one injector only, 
the practice was not necessarily reciprocated by the other injector, who often 
borrowed or loaned with other members of a social network.  Additionally, many 
respondents were unfamiliar with the risks associated with flushing and re-using 
filters.  A few respondents had participated in a safer injecting course and this 
approach should be expanded.  Peer interventions might also be considered; 
these methods have been found to be effective in reducing some risk behaviours 
among out-of-treatment IDUs and crack cocaine users (Cottler et al., 1998).     
 
Recommendation 2:  It is recommended that the DHSSPS develop gender 
specific information on the risks associated with injecting dependency.     
 
Some respondents in the study reported that they needed someone else to inject 
them, although the reasons for this assistance varied somewhat.  Males who 
relied on others to inject them often did so because their veins had been 
damaged through injection and they were currently injecting in hard-to-reach 
areas, e.g., the neck, back of a leg.  Females’ reliance on others to inject them 
tended to result from having smaller veins (as opposed to damaged veins) or 
because they had little knowledge of the injection process.    
 
Recommendation 3:  It is recommended that the importance of regular 
testing with effective pre- and post-test counselling should be emphasized 
and that the list of venues where testing is conducted should be expanded.   
 
Several respondents appeared to lack knowledge with regards to the need for 
regular testing for infectious disease.  Slightly more than half of the respondents 
were certain that they had undergone antibody testing for hepatitis C.  Others 
had never been tested for hepatitis C, B or HIV, or were confused about the type 
of test that was conducted.     
 
Recommendation 4:  It is recommended that outreach services be 
expanded to other areas of Northern Ireland, and that different strands of 
outreach are needed.   
 
Several respondents requested information from the researchers, and most of 
the requests pertained to accessibility of services, issues relating to current 
treatment, or aftercare.  These requests could easily be addressed through 
effective outreach.  The data suggest that two strands of outreach are needed.  
One strand of outreach should focus on respondents who are not in contact with 
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services.  A second strand should address issues relating to current treatment  
and aftercare.   
 
Recommendation 5:  It is recommended that some pharmacy-based 
schemes should offer a greater degree of privacy.   
 
The study found that some individuals were greatly concerned about privacy and 
confidentiality in pharmacy-based exchanges.  As a result, some respondents 
avoided using the exchanges and others used them sparingly.  The equipment is 
contained in a “box” and boxes should be placed discreetly in carry bags.   
 
Recommendation 6:  It is recommended that the number of needles/ 
syringes should be increased to 30 per visit, and that further incentives 
should be developed to encourage return supplies of used injecting 
equipment.    
 
Several respondents reported venous damage that made it difficult to administer 
injections.  Some people reported using several needles before a substance was 
injected properly.  The findings also indicate that a number of people rely on 
secondary exchanges (from other people who utilise the exchange) because they 
are concerned that they will be identified as an injector.  The data show that a 
limited supply of needles/syringes contributed to risk behaviours for infectious 
disease.         
 
Recommendation 7:  It is recommended that all staff in pharmacy-based 
exchanges, including counter employees who deal with customers, should 
receive training in the delivery of this service.  Training must include 
issues pertaining to customer relations.   
 
Although most respondents reported that they had established good relationships 
with staff in pharmacy-based exchanges, the data suggested a pattern of 
negative feedback regarding one exchange in particular.  Negative feedback 
from staff contributed to further risk-taking among some respondents.  The data 
indicate that customer relations in pharmacy-based exchanges have the potential 
for affecting public health.        
 
Recommendation 8:  It is recommended that the DHSSPS develop 
additional methods to distribute new injecting equipment to IDUs.   
 
The majority of respondents generally injected with one or more IDUs.  Among 
this group, most individuals tended to resist loaning or borrowing needles and 
syringes.  However, the social setting in which injection occurs (e.g., semi-public 
spaces) as well as individual circumstances (e.g., withdrawal or the anticipation 
of withdrawal) contributed to greater risk.  In many instances where respondents 
loaned or borrowed a needle/syringe, the practice occurred because new 
needles and syringes were not available.  The data show that the accessibility of 
new needles/syringes is hindered by various structural factors, including limited 
hours of pharmacy-based exchanges, geographic locations of exchanges, caps 
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on the number of needles/syringes per exchange, difficulties in purchasing 
needles/syringes, perceptions about stigma and concerns about confidentiality 
(largely from other customers) in exchanges.  Needle exchange represents one 
way to distribute new injecting equipment.  However, the source is limited in its 
ability to reach injectors who were interviewed for this study.     
 
Recommendation 9:  It is recommended that the DHSSPS develop different 
forms of information, support and advocacy for IDUs.   
 
The study found that several IDUs required information and advocacy and that 
without these services, relapse or continued risk taking are likely.  On several 
occasions, the researchers provided very basic services that could easily be 
addressed through outreach.  The information and advocacy provided by the 
researchers indicated a major gap in services.  Although individuals who had 
been in contact with the South Belfast Drug Outreach Team reported very 
favourable outcomes, the Team is for the most part restricted to a particular area 
of Belfast and resources are limited.       
 
Recommendation 10:  It is recommended that the DHSSPS or other 
government body review the training material currently provided by the 
PSNI regarding injecting equipment and injecting risk behaviours for 
infectious disease.  Based on this review of training material, additional 
training may be required with regards to the relationship between police 
practices and risk behaviours for infectious disease.  Training should 
incorporate a multi-agency approach that seeks to develop better 
relationships between the police and drug services and between police and 
staff working in needle exchange schemes.     
 
The study found that police practices, particularly in the Northern Board area, are 
at odds with public health initiatives in that the threat of arrest for possessing 
injection equipment contributed to risk behaviours among injectors.  Staff in drug 
services from the Western Board also reported to us that similar police practices 
have been observed in that area.       
 
Recommendation 11:  It is recommended that interventions be developed 
so that IDUS can increase their knowledge of benzodiazepine dependence 
and withdrawal, and that further research is needed with regards to the use 
of benzodiazepines among IDUs.   
 
The study found a high rate of benzodiazepine use among the respondents.  
Indeed, several respondents acknowledged their dependence on 
benzodiazepines.    One potential danger of benzodiazepine use concerns their 
link with hepatitis C infection, particularly among women (Cottler, Meeks and Ben 
Abdallah, 2002).  However, use of benzodiazepines is unlikely to change much 
within this group in the event that GPs are discouraged from prescribing.  In the 
event of such a policy, respondents would most likely access the substances 
from drug markets which would pose other risks and fail to address the problem 
of dependence.  The results from this study found that when GPs refused or 
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discontinued prescriptions for benzodiazepines, some respondents accessed the 
drug through illegal markets.            
 
Recommendation 12:  It is recommended that treatment modalities for 
cocaine and crack use are identified and implemented.   
 
The study found high rates of lifetime and recent injection of cocaine or crack 
cocaine.  Cocaine and crack cocaine injectors did so with greater frequency than 
heroin injectors.  Currently, there are fewer treatment options for cocaine and 
crack users compared to opiate users.     
 
Recommendation 13:  It is recommended that the DHSSPS identify the 
prevalence of hepatitis B and C and HIV among IDUs in-contact and not-in-
contact with drug services.   
 
The protocol used by the Northern Ireland Unlinked Anonymous Prevalence 
Monitoring Programme should be expanded to include IDUs who are not in 
contact with services.3  Given an expansion of the Programme, it would be 
important to utilise various strategies to recruit hard-to-reach IDUs.  The results 
from the present study indicate a very strong likelihood for an epidemic of 
hepatitis C virus among IDUs in Northern Ireland.  Several findings support this 
conclusion:  A) We did not ask people to share test results with us, however, of 
the 53 people who were certain that they had undergone antibody testing for 
hepatitis C, 30% reported that they were positive.  B) Most of the IDUs engaged 
recently in the loaning and borrowing of injection equipment.  C) Despite some or 
regular use of needle exchanges, respondents reported that accessibility to new 
needles/syringes was restricted at certain times or in particular settings.  D) A 
number of male and female IDUs engaged in the behaviour of flushing.  
Elsewhere, the practice has been linked with hepatitis C infection (Abdala et al, 
2004).  E) Approximately half the sample had resided in or visited “high risk” 
locales where they had frequented with other injectors, and we believe that the 
history and nature of social networks is important in the transmission of disease.  
Additionally, some respondents had been in prisons with a number of other 
injectors.  F) Several respondents appeared to lack knowledge with regards to 
the need for regular testing for infectious disease.  Others had never been tested, 
were confused about the type of test that was conducted and a few were 
uncertain whether they had been tested.  The data suggest that an epidemic is 
likely to occur first in the Eastern Board (primarily in the Belfast area), and then in 
the Northern Board.  On average, respondents in the Eastern Board had been 
injecting for longer periods of time, were less likely to be in treatment, were 
injecting more often, and knew considerably more IDUs with hepatitis C 
compared to respondents residing in the Northern Board.  Prevalence estimates 
of antibody hepatitis C with diverse groups of IDUs would assist with 
epidemiological monitoring.         
 
                                                 
3 The measures contained in the Monitoring instrument may need to be revised in order to 
increase the validity of self-reported “sharing.”    
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Recommendation 14:  In communities where injecting drug users reside, it 
is recommended that drug outreach teams in conjunction with community 
workers should have on-going discussions about the nature of heroin 
addiction and the importance of treatment and needle exchange with 
identified informal “leaders” within those communities.  This approach is 
particularly important in small towns and villages.     
 
Injectors perceived that their behaviours are greatly stigmatised.  In particular, 
respondents who reside in small towns, villages and rural areas voiced 
considerable concern that others knew of or would learn about their “injector” 
status.   
 
Recommendation 15:  Considerable work is needed to address the needs 
of women injectors.  It is recommended that the DHSSPS adopt the 
recommendations in the Home Office report, Women Drug Users and Drugs 
Service Provision: Service-Level Responses to Engagement and Retention 
(Becker and Duffy, 2002).          
 
Women with children were more likely than men to voice concern about being 
identified as drug injectors.  They were more likely than men to avoid treatment, 
to avoid testing, and to avoid disclosing drug use to their GPs because of their 
concerns.  We observed that the perceived community stigma was a factor 
contributing to further risk taking, and at times, relapse.      
 
Recommendation 16:  It is recommended that the time to avail of detox and 
treatment should be significantly reduced.  Treatment on demand is the 
preferred goal although realistically, resources are unlikely to be available 
to meet this objective.  Still though, all efforts should be utilised in order to 
reduce the waiting time to a 30-day period.        
 
Several respondents residing in the Eastern and Northern Health and Social 
Service Board areas reported lengthy waits for placement in a detox setting.  In 
most instances, the placement was required before maintenance could begin.  In 
the Northern Board, respondents reported that the Addiction Unit had space for 
ten respondents only, and there was some confusion over whether the ten 
spaces were “reserved” for heroin users only.  The number of detox “beds” is 
seriously limited in Northern Ireland.       
 
Recommendation 17:  It is recommended that an independent evaluation be 
conducted with regards to the effectiveness of drug services that have the 
potential to assist injecting drug users.  The evaluation should incorporate 
the views of clients, staff, GPs and possibly other individuals.   
 
Although some respondents reported that they benefited greatly from treatment 
services and that staff-client relationships were very good, several others 
identified negative experiences in treatment settings and these experiences 
shaped their current views about drug services.  Moreover, views about drug 
services tended to vary across board areas.  In particular, “blanket” policies in 
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which consultant psychiatrists refuse to prescribe a particular substitute drug 
(i.e., Subutex or methadone) to any client should be evaluated closely by the 
DHSSPS.   
 
Recommendation 18:  It is recommended that research explore the links 
among depression, initiation into drug use and injecting, and relapse.   
 
During the initial interviews, respondents were not questioned about depression.  
The issue surfaced shortly thereafter and we then began to enquire about 
depression.  A large number of respondents reported that they were in receipt of 
prescriptions for anti-depressants.  Depression has been linked with risk 
behaviours for infectious disease (Lovell, 2002).   
 
Recommendation 19:  It is recommended that further interventions are 
needed to encourage condom use among IDUs.  Encouraging change 
among long-term partners represents a significant challenge in terms of 
public health.       
 
This study found that sexual risk taking was rare among long-term injectors; 
sexual interest or arousal had diminished over time, even when respondents 
were involved with partners over the course of several years.  The length of the 
injection career, however, was associated with sexual risk taking.  That is, 
several younger IDUs were involved with female partners who had never 
injected. In these relationships, most respondents reported having engaged in 
unprotected sex with one partner in the past 30 days.     
 
Recommendation 20:  It is recommended that the DHSSPS further develop 
ways to increase the accessibility of training among GPs.  Training issues 
should include the nature of drug dependence, relapse and injecting 
behaviours.       
 
Although some respondents reported having excellent relationships with their 
GPs, several others noted that GPs lacked knowledge about drug addiction or 
were unsympathetic.  A number of respondents changed GPs on multiple 
occasions, eventually relying on drug services or outreach to locate an 
appropriate GP.     
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APPENDIX 
 
Questions asked and topics covered in the Interview Guide 
 
1. Tell me about the first time that you injected (e.g., drug injected, age at first 
injection, place of first injection, number of people who were present and whether 
they all were injecting, relationships with people in the setting).  
 
2. If someone injected you this first time, did you know the person?  Were they a 
stranger, acquaintance, or friend?    
 
3. What was the experience like for you?  Prior to that experience did you think 
that you would ever inject a drug? 
 
4.  How soon after the first injection, did you or someone else inject you again?  
(IN DAYS, WEEKS OR MONTHS) 
 
5.  Tell me about the last time that you injected or that someone injected you.  
When did this occur?  What drug(s) were injected?      
 
6.  The last time that you injected or that someone else injected you, were you by 
yourself?  How many people were with you?  Had you meant them all before that 
time?  Did they all inject?  If someone present did not inject, do you know 
whether they have ever injected?    
 
7.  If more than one person injected, how many needles were present?  Were 
you the first to inject or did someone else inject first?  What was the reason for 
that order of injection, that is, why did so-and-so inject first, and another person 
inject second?    
 
8.  Take me through the injection process.  Describe it for me.    
 
9.  What drug(s) do you inject most often?   Would this drug be your favourite or 
preferred drug?  Tell me about that.   
 
10. Think about the drug that you inject most often.  I’m going to ask you 5 
questions about this drug, and for each question I’d like you to choose one 
answer from the list of answers that I give you.   
 
11.  Do you think your use of _________ is out of control?  (Never/Almost never, 
Sometimes, Often, Always/Nearly always) 
 
12.  Does the prospect of missing a fix or a dose of __________  make you 
anxious or worried? 
(Never/Almost never, Sometimes, Often, Always/Nearly always) 
 
13.  Do you worry about your use of ___________ ?  (Never/Almost never, 
Sometimes, Often, Always/Nearly always) 
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14.  Do you wish you could stop using __________ ? 
(Never/Almost never, Sometimes, Often, Always/Nearly always) 
 
15.  How difficult do you find it to stop or go without ______________ ?  
(Never/Almost never, Sometimes, Often, Always/Nearly always) 
 
16.  What other drugs have you injected?  Have you injected more than one drug 
at the same time?  If so, what drugs have you injected at the same time?  Do you 
inject differently depending on what drug you are injecting?  Tell me about that.   
 
17.  How many times have you injected in the past 30 days (that is, since 
_______________ (SHOW CALENDAR)    (NOTE THAT THIS QUESTION 
FOCUSES ON THE NUMBER OF TIMES RATHER THAN THE NUMBER OF 
DAYS) 
 
18.  In the past 30 days, how many different people have you injected with? 
(SHOW CALENDAR)   Were these people friends of yours?  A partner?  Did you 
inject with any strangers or with people that you didn’t know very well?   
 
19.  Do you often inject with this same group of people (or same person)?    
 
20.  Tell me about the different drugs that you have injected in the last 30 days? 
 
21.  In the past 30 days, how many times have you filled a syringe, and used it 
when it had already been used by someone else? 
 
22.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
23.  In the past 30 days, how many times did you let someone else fill their 
syringe from one that you had already used? 
 
24.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
25.  In the past 30 days, how many times did you draw up from a container, such 
as a glass or a cup, into which someone else had put a used syringe? 
 
26.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
27.  In the past 30 days, how many times did you put a used needle into a 
container such as a glass or cup, that was then used by someone else? 
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28.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY) (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
29.  In the past 30 days, how many times did you use a filter that someone else 
had already used? 
 
30.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
31.  In the past 30 days, how many times did you use someone else’s rinse 
water?   
 
32.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
33.  In the past 30 days, how many times did someone else use your rinse 
water?   
 
34.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
35.  In the past 30 days, how many times did you let someone else use a filter 
that you had used?   
 
36.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 




38.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
 
39.  In the past 30 days, how many times did you use works that had been put in 
the same container as someone else’s used works?  What kind of container was 
this?   
 
40.  What was your relationship to these other people?  (CIRCLE ALL THAT 
APPLY)  (Sex partner, Friend not sex partner, Other relation, Acquaintance, 
Stranger) 
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41.  Have you used the same needle more than once during the past 30 days?  
Did you ever attempt to mark it some way so that you would know that it was 
yours?  Tell me about that.   
 
42.  In the past 30 days, have you cleaned any needle or syringe?  (If so) About 
how often do you clean needles/syringes?  Some of the time, all the time?  Does 
cleaning depend upon who you are injecting with?  How did you clean them or 
what did you use to clean them?   
 
43.  Tell me about “flushing.”  What does the word mean to you?  About how 
many times in the past 30 days have you flushed in the presence of other people 
who were injecting?  Were others flushing as well?  Think about the last time that 
you flushed in a group setting.   
 
44.  Have you ever used a needle exchange in N. Ireland?  If so, tell me about 
that experience.    
 
45.  How many times have you used a needle exchange in the past 30 days 
(SHOW CALENDAR)   
 
46.  (Persons who have never used a needle exchange in N. Ireland)  If you have 
never used a needle exchange in N. Ireland, why have you not done so?   
 
47.  Is a needle exchange a good way for you to get new needles?  Is there any 
other way that you can think of that would help people get new needles?   
 
48.  In the past 30 days, from what other sources have you obtained new 
needles/syringes?     
 
49.  In the past 30 days, from what other sources have you obtained used 
needles/syringes? 
 
50.  Have the police ever found needles or other paraphernalia on you or in your 
home?  Tell me about that.  When did this occur? 
 
51.  Have you ever used benzodiazepines?  Tell me about that.  (Have you used 
benzodiazepines in the past 30 days?  How often have you used 
benzodiazepines in the past 30 days?  When do you prefer to use them?  Are 
they prescribed?  Why do you use them? How do you use them?) 
 
52.  Do you drink alcohol?  How many days in the past 30 days have you drank 
alcohol?  (SHOW CALENDAR)  In the past 7 days, how many days have your 
drank alcohol?  What was your daily intake?         
 
53.  In the past 30 days, how many times have you had sexual intercourse? 
 
54.  In the past 30 days, with how many different partners have you had sexual 
intercourse? 
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55.  In the past 30 days, have you used a condom?  (Try and get at the whether 
condoms were 1) always used, 2) sometimes used, or 3) never used.  Try and 
note whether condoms are used with regular sex partners or other sex partners)  
 
56.  Do you have a GP?   
 
57.  Have you ever visited a GP to seek help for your drug use?  If not, why not?  
If so, tell me how the GP responded.   
 
58.  Has a GP ever prescribed something to help you with your own drug use?  If 
so, what drugs have you been prescribed?  Did these drugs help you? 
 
59.  Tell me about how you and your GP (or previous GP) get on? 
 
60.  Have you ever read about or has anyone ever told you how to 1) inject 
correctly or safely?  2) reduce the risk of overdose?  Was this person a friend, 
drug worker, GP? 
 
61.  Do you have a dentist?  [If so] Do you visit on a regular basis 
and for what reasons?'  Have you ever discussed your drug use with the 
dentist? [If so] How has s/he responded? 
 
62.  Tell me about your health.  Have you had any health problems that might be 
related to drug use?  If so, what do you do about these problems?            
 
63.  How do you feel about your own drug use?  Do you feel OK about it?  Would 
you like to reduce the amount that you use?   
 
64.  Have you ever attended a drug service or drug treatment agency in N. 
Ireland?  When did this occur?  Tell me about those experiences.   
 
65.  Have you approached some other service, agency, or organisation for help 
with your drug use?  When did this occur?  Tell me about that.    
 
66.  Are you in treatment now or are you attending a drug service now?   
 
67.  Would you like treatment now?  Why or why not? 
 
68.  Have you ever been given methadone, Subutex, or Britlofex here?  Tell me 
about those experiences.  (Get at dosage, whether the substances were used for 
detox only or for maintenance) 
 
69.  I don’t want to ask you about test results, but have you ever been tested for 
HIV?  [If so] How many times?  [If not] Why have you not been tested?   
 
70.  Have you ever been tested for Hepatitis C?  If so: How many times?  If not: 
Why have you not been tested?   
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71.  Have you ever been tested for Hepatitis B?  If so: How many times?  If not: 
Why have you not been tested?   
 
72.  Have you ever been vaccinated for Hep B?  (Did you complete the series of 
vaccinations?)  Tell me about this experience.    
 
73.  How many injectors would you know in N. Ireland? 
 
74.  About how many injectors or friends of injectors in N. Ireland do you know 
who have HIV?  Hepatitis C?  Hepatitis B?     
 
75.  Gender of respondent: 
 
76.  What year were you born? 
 
77.  Employed?   
 
78.  Tell me about any education or training programmes that you have 
completed.   
 
79. County of residence  
 
80.  County where from  
 
81.  Currently lives in:  a large city, a small city, a town, rural location, other 
 
82.  Health Board  
 
83.  Do you live alone, or with other people?   
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